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MODELLING AND DISRUPTING PROTEIN INTERACTIONS 
Nicolas Arcenio Pabon, Ph.D. 
University of Pittsburgh, 2018 
Rational drug design requires a deep understanding of protein interactions, both in terms of the structural 
mechanisms that regulate binding of individual molecules and the broader, pathway- and cell-level effects 
of disrupting protein interaction networks. This thesis presents work that stems from these ideas, 
discussing contributions to a number of current challenges in the field of drug discovery. First, we describe 
how structural flexibility is leveraged by ‘selectively promiscuous’ protein interfaces – enabling them to 
bind specifically to several distinctly shaped ligands. Taking PD-1 as a case study, we demonstrate using 
molecular dynamics simulations how the flexible receptor interface recognizes conserved ‘trigger’ motifs 
on its cognate ligands’ interfaces. Trigger interactions, which we show are also exploited by a recent 
blockbuster PD-1 inhibitor, drive the initial steps of an induced-fit binding pathway that then ‘splits’ into 
distinct, ligand-specific bound states. Second, we present a hybrid genomic and structural pipeline for 
genome-scale identification of protein targets for bioactive compounds. We train a random forest 
classifier to predict compound-target interactions from compound treatment and gene knockdown gene 
expression signatures in multiple cell types. Refining genomic predictions with a structure-based screen, 
we achieve top-10/top-100 target prediction accuracies of 26%/41%, respectively, on a validation set of 
152 FDA-approved drugs, and validate previously unknown small molecule modulators of HRAS, KRAS, 
CHIP, and PDK1. Third, we present a strategy that combines transcriptomic and structural analyses with 
single-cell microscopy to predict small molecule inhibitors of TNF-induced NF-kB signaling and elucidate 
v 
the network response. Validating two novel pathway inhibitors that disrupt the protein network upstream 
of IKK and NF-kB, our findings suggest that a network-centric drug discovery approach is a promising 
strategy to evaluate the impact of pharmacologic intervention in signaling. Last, we introduce DrugQuery 
(DQ), a structure-based public web server for small molecule target prediction. DQ docks user-submitted 
small molecules against a target library of 7957 predicted binding sites on 1245 human proteins. The 
server achieved a top-decile target prediction accuracy of 68% on a validation set of 95 FDA-approved 
drugs and 86% on a validation set of 102 FXR-binding compounds from the 2017 D3R Grand Challenge 2. 
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1.0 INTRODUCTION 
Rational drug design is, in essence, the effort to develop leads in drug discovery by leveraging all known 
theoretical and experimental knowledge of the system one is trying to drug [1]. Owing to decades of 
progress in fields such as computer science, statistics, machine learning, genomics, molecular biology, 
and biochemistry, rational drug design has obtained a central role in medicinal chemistry as a more cost- 
and time-efficient complement to traditional high-throughput screening [2]. Despite significant 
technological and scientific advances, however, global attrition rates in pharmaceutical programs are 
climbing, as is the average R&D cost per drug approved [3-5]. We currently face important challenges in 
two key areas of rational drug design: structure-based methods [6], which attempt to leverage the 3D 
structures of protein disease targets to discover small molecule (ant)agonists, and genomic methods [7], 
which attempt to leverage gene expression and other multi-omic data to identify disease targets and 
predict potential inhibitors. These challenges include: (1) understanding how the flexibility of protein 
interfaces regulates specificity and promiscuity to binding partners, (2) predicting the protein targets of 
bioactive small molecules, (3) developing strategies for small molecule modulation of complex signaling 
networks, and (4) large-scale structure-based compound-centric target screening. In this dissertation we 
will discuss our advances in these four areas.  
1.1 OUTLINE 
This dissertation is organized as follows: 
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In Chapter 2.0 we discuss how the human PD-1 receptor exploits interface flexibility to achieve 
“selectively promiscuous” binding to structurally-distinct cognate ligands. We use molecular dynamics 
simulations to identify the mechanisms that trigger structural transitions between the unbound and 
bound PD-1 interface conformations. Our results show that conserved “triggers” on the ligand interfaces 
drive the initial steps of an induced-fit binding pathway that then splits into two distinct bound states, 
with PD-1’s flexibility accommodating the non-conserved, trigger-adjacent ligand features. We 
demonstrate that PD’s ‘selective promiscuity’ results largely from the displacement of its interface 
residue Asn66 by trigger interactions, which switches the receptor interface from flat and polar to either 
a hydrophobic patch or a hydrophobic cavity, depending on which ligand drives the induced fit 
transition. A recently published crystal structure of Pembrolizumab, a blockbuster PD-1 - targeting 
immune checkpoint inhibitor, confirms the importance of conserved triggering interactions in binding to 
flexible protein interfaces. 
 
In Chapter 3.0 we demonstrate a hybrid genomic & structural target prediction pipeline for bioactive 
small molecules. Using gene expression data from thousands of small molecule treatment and gene 
knockdown experiments in live cells, we train a random forest classifier to predict compound-protein 
interactions from correlations between compound & knockdown expression signatures. We then refine 
our genomic target predictions with structural modeling and molecular docking. On a validation set of 
152 FDA-approved drugs and 3104 potential targets we achieve top-10 and top-100 target prediction 
accuracies of 26% and 41%, respectively, doubling the accuracy of previous gene expression-based 
methods. We additionally validate several previously unknown small molecule modulators of HRAS, 
KRAS, CHIP, and PDK1. 
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In Chapter 4.0 we discuss an application of the insight we gained from Chapter 3.0 – an extension of our 
pipeline that combines its transcriptomic and structural analysis with single-cell microscopy to predict 
small molecule disruptors of TNF-induced NF-kB signaling and characterize the response of the 
disrupted protein interaction network. Using live-cell fluorescence assays to monitor signaling dynamics 
of cells treated with predicted disruptors of the canonical NF-kB pathway, we identify two compounds 
that inhibit formation of the mature TNFR1 complex, preventing recruitment of the IKK complex and 
eliminating NF-kB translocation to the nucleus. 
 
In Chapter 5.0 we present a public web server that we developed for molecular docking-based small 
molecule target fishing. The server, called DrugQuery (DQ), docks user-uploaded small molecules against 
1245 human proteins and returns ranked target predictions and structural models of predicted binding 
modes. Approximately 8000 precomputed binding sites across the DQ target library are stored in a 
database and used to accelerate docking, which enables results to be returned in mere hours for most 
small molecules. On a validation set of 95 FDA-approved with known target structures, DQ correctly 
predicts the known target in the top decile of potential targets 68% of the time. On a separate validation 
set of 102 congeneric FXR-binding compounds from the 2017 D3R Grand Challenge 2, DQ achieves a 
86% top decile prediction accuracy. 
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2.0 PROBING PROTEIN FLEXIBILITY REVEALS A MECHANISM FOR SELECTIVE PROMISCUITY 
 
 
 
 
2.1 INTRODUCTION 
 
 
Structural and proteomic research over the past decade has supplanted the traditional structure-function 
paradigm by establishing the functional relevance of protein dynamics [8-13]. In particular, eukaryotic 
regulatory and signaling proteins are skewed towards notably higher degrees of flexibility when compared 
to other functional categories [14, 15]. Regulatory proteins also tend towards comparatively higher 
degrees of binding promiscuity, and we have previously shown thermodynamically how the entropy 
associated with their flexibility can relate to their specificity towards multiple binding partners [14]. 
However, a structural understanding of how this selective promiscuity is achieved is still lacking. 
 
Flexible human regulatory proteins such as MDM2 and PD-1 usually only crystallize when ligand-bound. 
Although Nuclear Magnetic Resonance (NMR) can occasionally resolve unbound (apo) structures of these 
proteins, it is noteworthy that their apo NMR ensembles often deviate from their bound crystal structures 
[16-22]. Thus, for many such proteins, available structural data do not capture the full binding dynamics, 
and the pathway from the apo, non-bound-like state to the bound-like state is unclear. This lack of data 
obscures the mechanistic connection between interface flexibility, binding promiscuity, and ligand 
specificity. Moreover, given that many regulatory proteins are promising drug targets, this missing puzzle 
piece often spells failure for drug design efforts that only target the bound-like state, assuming that this 
state is available in the apo ensemble. Rational approaches to target flexible proteins will thus benefit 
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from new methods that can reveal the binding pathways connecting the non-bound-like to the bound-
like states.  
 
Binding to flexible receptors is traditionally described by conformational selection [23, 24] or induced fit 
[25] mechanisms, and NMR techniques are often used to distinguish between these two (Figure 2.1). 
Generally speaking, one assumes a conformational selection scenario if the apo protein ensemble samples 
bound-like states (apoBL) [26, 27]. If not, one assumes induced fit [16]. In reality, whether a protein-protein 
interaction occurs via conformational selection or induced fit depends on the flux of the system through 
the two alternate pathways from the non-bound-like apo state (apoNBL) to the bound-like encounter 
complex (ECBL) [28]. Flux through the conformational selection pathway is limited by the free energy 
difference between the apoBL and apoNBL states, ∆𝐺#$%&', which determines the fractional population of the 
bound-like state and thus restricts when selection-association with the ligand can occur. On the other 
hand, flux through the induced fit pathway is for the most part independent of ∆𝐺#$%&', as the ligand is 
presumed to be able to associate with all apo receptor microstates. Instead, flux through this pathway is 
limited by the free energy difference between the ECBL and the non-bound-like encounter complex (ECNBL), ∆𝐺#$() , which is a function of specific interactions between receptor and ligand, and the energy barrier 
between these states. Both pathways terminate via a ubiquitous optimization step in which minor 
structural rearrangements at the ECBL interface lead to the high affinity complex. 
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Figure 2.1. General mechanism for ligand binding to flexible receptor. In the conformational selection 
pathway, the ligand docks to the bound-like (BL) form of the apo receptor (apoBL) to form the bound-like 
encounter complex (ECBL). In the induced fit pathway, the ligand docks to the non-bound-like (NBL) form 
of the apo receptor (apoNBL) to form the non-bound-like encounter complex (ECNBL). Intermolecular 
interactions then drive structural transitions to the ECBL. Both pathways end with a final induced fit step 
that optimizes interface side chains, transitioning to the high affinity complex (HAC). The binding 
mechanism also highlights an anchor residue often found to be important in molecular recognition [29]. 
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To shed light on the structural basis of selective promiscuity in the aforementioned class of flexible-
interface multi-ligand proteins, we study the binding mechanism of PD-1 to its cognate ligands PD-L1 and 
PD-L2. Human PD-1 is a T cell receptor and immune response regulator that has recently emerged as a 
breakthrough anti-cancer target [30, 31]. NMR and crystallographic studies have revealed the flexibility 
of the PD-1 interface by showing that its apo and bound conformations are very different [19-22] (Figure 
2.2, Figure 2.13), suggestive of an induced fit mechanism. Specifically, while the apo PD-1 interface shows 
a polar surface around Asn66 with an unmatched NH2 (Figure 2.2a), in complex this NH2 group forms two 
hydrogen bonds, with the PD-L1 – bound interface exhibiting a hydrophobic patch around Ile126 (Figure 
2.2b), and the PD-L2 – bound interface forming a large hydrophobic cavity flanked by Ile126 and Ile134 
(Figure 2.2c, Figure 2.14).  
 
To date, no small molecular weight PD-1 inhibitors have been reported in the literature despite the 
importance of this blockbuster target [30-32]. This was somewhat surprising, since the Trp110 binding site 
observed in the PD-L2 – bound cocrystal (Figure 2.2c) displays two key characteristics known to be 
favorable for ligand binding: concavity [33, 34] and hydrophobicity [35]. It is reasonable to assume that 
the flexibility of the Trp110 pocket, and the fact that in the apo state it is largely occluded by the 
unmatched, polar NH2 group of Asn66 (Figure 2.2a,d), would present significant obstacles to traditional 
structure-based drug-design methods attempting to target this cavity [36]. Thus, efforts to model the 
binding mechanism of PD-1 would not only shed light on nature’s design principles for flexible and 
promiscuous protein-protein interfaces, but they may also offer novel avenues for pursuing rational drug 
design against this and other high-impact targets. 
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Figure 2.2. Flexibility of the PD-1 binding interface. (a) The apo PD-1 binding interface [19], showing a 
flat, polar, core binding interface. Surface residues that shape the core binding interface are labelled. (b) 
The core PD-1 (green) - PD-L1 (yellow) binding interface, showing a flat hydrophobic receptor surface [20]. 
White dashed lines indicate hydrogen bonds between PD-L1 side chains. (c) The core PD-1 (cyan) – PD-L2 
(orange) binding interface, showing a large hydrophobic receptor cavity [21]. White dashed lines indicate 
hydrogen bonds between PD-L2 side chains. Note that the conserved anchor residue Tyr123/112 is 
present in both (b) and (c). (d) Fractional occlusion of each bound-like Trp110 and Tyr123/112 atom 
position in the NMR ensemble of apo PD-1. Numerical values at each atom position denote the fraction 
of NMR frames that overlap, or “occlude”, that position (see Chapter 2.4 Methods for full details of how 
fractional occlusion is calculated). Aside from the Cβ, the Trp110 pocket is mostly occluded in the apo PD-
1 ensemble, whereas the Tyr123/112 anchor pocket is largely open. (e) Overlay of apo, PD-L1 – bound, 
and PD-L2 – bound structures of PD-1 defining the “open” and “closed” states of PD-1 residues Asn66 and 
Ile126 in relation to the open and closed states of the Trp110 binding pocket.    
 9 
To study the mechanism of PD-1 binding we use molecular dynamics simulations (MDs) to identify and 
quantify the effects of intermolecular interactions on the PD-1 binding interface. We first estimate ∆𝐺#$%&' 
for the free receptor and demonstrate that apoBL states are exceedingly rare. We then estimate ∆𝐺#$()  for 
PD-1 interacting with various peptide constructs that mimic distinct subsets of ligand interface motifs 
(Figure 2.3) and identify the critical features that trigger shifts in the PD-1 conformational ensemble 
towards the bound-like states. By quantifying the energetic contribution of each triggering contact in the 
ECNBL, we rationalize how PD-1 uses flexibility to simultaneously achieve both promiscuity, i.e., binding to 
multiple ligands, and specificity. We show that a conserved set of three contacts in the PD-1 encounter 
complexes with PD-L1/2 progressively lowers the free energy of bound-like receptor states with respect 
to the non-bound-like state. These molecular triggers reshape the non-bound-like hydrophilic interface 
around Asn66 into a bound-like hydrophobic surface. A fourth contact that differs by a single atom 
stabilizes this surface into either a shallow patch that interacts with Ala121 in PD-L1, or a deep cavity that 
buries Trp110 in PD-L2.  
 
We find that these triggers, which include the anchor Tyr123/112 in PD-L1/PD-L2 (Figure 2.2b,c,d) [29], 
are highly conserved across species [21] and drive quantitatively similar, kinetically efficient downhill 
binding pathways. The importance of these triggers is underscored by the PD-1 – targeting, anti-cancer 
antibody pembrolizumab, which evolved via a distinct evolutionary pathway yet, as we show, exploits 
some of the same triggering machinery as PD-1’s natural ligands. Finally, we suggest how these induced-
fit triggers could be used in rational, small-molecule drug discovery by studying the binding mode of a 
potent macrocyclic PD-1 inhibitor. Collectively, our findings demonstrate how nature exploits structural 
flexibility to achieve selective binding promiscuity in regulatory proteins.  
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Figure 2.3. Structures of PD-L1/2 – mimicking peptides used to probe PD-1 interface dynamics. Left: core 
interface binding residues of (a) PD-L1 and (b) PD-L2 in their bound-like conformations. Right: peptides 
that were simulated in the presence of apo PD-1 in order to identify the triggers of induced fit interface 
deformations: (c) Y, (d) DY, (e) GGG, (f) GGY, (g) GDG, (h) ADG, (i) GDY, (j) ADY, and (k) mGDV. 
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2.2 RESULTS 
 
 
2.2.1 Open and closed states of PD-1 Asn66 and Ile126 describe a hydrophilic or hydrophobic 
interface.  
 
Analysis of aligned PD-1 structures (Figure 2.2) led us to classify the bound-like and non-bound-like 
conformational states using two binary order parameters defined by the ‘open’ or ‘closed’ states of Asn66 
and Ile126. Namely, for a non-bound-like interface Asn66 is closed and Ile126 is open; for the PD-L1-
specific bound-like state Asn66 is open and Ile126 is closed; and for the PD-L2-specific bound-like state 
both Asn66 and Ile126 are open (Figure 2.2e). In the PD-L1 – bound state, the interface exhibits a large 
hydrophobic patch that interacts with the side chain of ligand interface residue Ala121 (Figure 2.2b). In 
the PD-L2 – bound state, the interface exhibits a deep hydrophobic cavity that buries ligand residue 
Trp110 (Figure 2.2c). Neither this hydrophobic patch nor deep cavity is sampled in the apo PD-1 NMR 
ensemble, where, instead, the closed state of Asn66 blocks the Trp110 binding pocket by exposing its NH2 
group (Figure 2.2a,e, Figure 2.14), making a hydrophilic site. MDs of apo PD-1 confirm that Asn66 remains 
closed (Figure 2.4a), stabilized by a hydrogen bond with Lys78 that is also present in NMR structures 
(Figure 2.5a). These findings suggest that specific interactions between apo PD-1 and a nearby ligand 
might be required to open Asn66 and reshape the hydrophilic interface into its hydrophobic bound-like 
states. 
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Figure 2.4. Dynamics of PD-1 binding interface in the presence of different ligands. (a) Rolling averages 
of distance between Trp110_NE1 (from bound PD-L2) and Asn66_ND2 from MDs of apo PD-1 (blue) alone 
and interacting with GGG (maroon) and GDG (red) peptides. Only GDG peptide sequesters Asn66 away 
from Trp110 binding pocket. (b) Rolling averages of PD-1 binding cavity volume from simulations of apo 
PD-1 alone (blue) and interacting with GDG (red) and GDY (orange) peptides shows that only GDY stabilizes 
an open cavity. (c) Ile126 Χ1 rotamer angle from MDs of apo PD-1 interacting with GDG (red), GDY 
(orange), and ADY (yellow) peptides. Peptide ADY and GDY position Ile126 in the closed and open states, 
respectively (as in Figure 2.2e). Replicate trajectories for panels a, b, and c are shown in Figure 2.16.   (d) 
Fractional occlusion of each bound-like Trp110 atom position in simulations of PD-1 interacting with the 
GDY peptide show an open Trp110 binding pocket. The fractional occlusion of a Trp110 atom position is 
defined as the percentage of simulation frames in which a PD-1 atom overlaps, or “occludes”, that position 
(see Chapter 2.4 Methods for full details of how fractional occlusion is calculated). (e) Fractional occlusion 
of each bound-like Trp110 atom position in simulations of PD-1 interacting with the ADY peptide show a 
closed Trp110 binding pocket. 
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Figure 2.5. Hydrogen bond network of PD-1 Asn66 in different contexts. (a) NMR structure of the 
dominant apo, non-bound-like state of the human PD-1 interface [19]. Asn66 is in the closed state, 
forming a single hydrogen bond with Lys78. (b) Cocrystal structure of the human PD-1 – PD-L1 complex 
[20]. PD-1 bound-like interface shows Asn66 in the open state, forming two hydrogen bonds with the 
ligand Ala121 backbone and the neighboring Tyr68. For clarity only relevant ligand atoms are shown. (c) 
Cocrystal structure of the murine PD-1 – PD-L2 complex [21]. PD-1 bound-like interface shows Asn66 is in 
the open state, forming two hydrogen bonds with the ligand Trp110 backbone and a crystal water 
stabilized by neighboring residue Asn68. (d) Simulation snapshot of human PD-1 interacting with the GDG 
peptide, showing the same hydrogen bond network as in (b). (e) Simulation snapshot of human PD-1 Y68N 
mutant interacting with the GDG peptide, showing the same water-mediated hydrogen bond network as 
in (c). 
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2.2.2 Bound-like conformations of unbound Tyr123/112 in PD-L1/2 facilitates molecular recognition.  
 
For both induced fit and conformational selection, the association of the apo receptor and ligand is driven 
mainly by diffusion [37, 38]. It has been shown that often protein-protein interactions stabilize the initial 
encounter complex through the burial of a bound-like anchor motif on the ligand [29], which allows 
subsequent, longer-timescale intermolecular interactions to take shape. Co-crystal structures, MDs and 
docking studies of PD-L1/2 suggest that the homologous interface residues Tyr123/112 (see Figure 2.2b,c) 
may serve as anchors. Specifically, MDs of apo PD-L1/2 show that Tyr123/112 remain within 0.5 Å heavy 
atom RMSD of their bound-like conformations 88 ± 16 % of the time. Furthermore, the Tyr123/112 binding 
pocket is unobstructed in the apo PD-1 NMR ensemble (Figure 2.2d), facilitating immediate burial of the 
side chain upon association. Docking exercises also point to the stabilizing role of the Tyr anchor. Namely, 
ClusPro [39] successfully re-docked the wild-type human PD-1 – PD-L1 co-crystal [20], but it failed for 
single-residue PD-L1 mutants Y123G and Y123A (Table 2.1). Collectively, these results suggest an anchor 
role for Tyr123/112 that facilitates molecular recognition between non-bound-like apo PD-1 and its 
ligands (as sketched in Figure 2.1). 
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Table 2.1. Anchor Tyr123 is key determinant of bound-like docked conformations. Backbone RMSD of 
top 10 ClusPro [39] predicted PD-L1 binding modes to the human PD-1 – PD-L1 cocrystal (PDB: 4ZQK). 
RMSDs shown for docked wild type human PD-L1 (WT) and for docked PD-L1 anchor mutants Y123G and 
Y123A. 
 
Docked PD-L1 Backbone RMSD 
(Å) to 4ZQK PD-L1 
ClusPro Model WT Y123G Y123A 
0 4.65 8.8 49.7 
1 54.0 38.2 49.1 
2 49.5 49.1 39.2 
3 47.5 40.4 40.4 
4 39.4 49.4 48.5 
5 48.0 40.07 53.2 
6 45.8 53.2 49.5 
7 40.6 46.5 48.1 
8 48.6 47.8 47.6 
9 50.7 48.7 50.4 
 
 
 
2.2.3 Conserved PD-L1/2 Asp122/111 form a specific intermolecular hydrogen bond network that 
opens PD-1 Asn66 and switches the receptor interface from hydrophilic to hydrophobic.  
 
Co-crystal structures of bound PD-1 exhibit an open Asn66 that forms two hydrogen bonds: the first with 
the backbone oxygen of homologous PD-L1/2 Ala121/Trp110, and the second with either PD-1 Tyr68 
(human PD-1 - PD-L1 complex) or a crystal water (murine PD-1 – PD-L2 complex) (Figure 2.5b,c). MDs of 
PD-1 in complex with a GGG peptide positioned to mimic the backbone of PD-L1/2 residues ADY123 and 
WDY112, respectively, show that Asn66 fluctuates back and forth between a bound-like open state, where 
it makes the aforementioned backbone hydrogen bond to the GGG peptide, and the non-bound-like 
closed state, where it is bonded to PD-1 Lys78 (Figure 2.4a). On the other hand, simulations with a GDG 
peptide show that the Asp122/111 mimic forms a hydrogen bond to the Tyr68 OH group, stabilizing a 
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Tyr68 rotamer that can simultaneously hydrogen bond to the NH2 of Asn66 (Figure 2.5d). Together, this 
Asn66 – Tyr68 hydrogen bond and the aforementioned Asn66 – backbone hydrogen bond stabilize the 
bound-like open state of Asn66 (Figure 2.4a).  
 
The robust, four-membered hydrogen bond network between the Ala121/Trp110 backbone mimic, 
Asn66, Tyr68, and the Asp122/111 mimic that we observe in GDG MDs is fully consistent with all available 
structures and mutagenesis experiments. Namely, the hydrogen bonds rationalize the conservation of 
Asp122/111 in all known PD-L1/2 sequences and explain PD-L2 mutagenesis studies showing that the 
D111A mutation abolishes binding to PD-1 [21]. MDs of apo PD-L1/2 further support the importance of 
Asp122/111 interactions in the encounter complex by showing that this side chain remains within 0.4 Å 
RMSD of its bound-like conformation 82 ± 25 % of the time. The stabilization of the bound-like Asp122/111 
side chain in simulation is achieved via hydrogen bonds with the neighboring Lys124/113, bonds which 
are also observed in bound cocrystal structures of PD-1 (Figure 2.2b,c). The importance of this stabilizing 
interaction is underscored by the fact that the K124S and K113A point mutations in PD-L1 and PD-L2, 
respectively, both abolish binding to PD-1 [21, 22]. 
 
PD-1 ligands open Asn66 by offering two novel hydrogen bonds (with the Ala121/Trp110 backbone and 
Tyr68) that out-compete the single Lys78 hydrogen bond that stabilizes the closed state. Interestingly, the 
one known PD-1 sequence that diverges at the Tyr68 position is murine PD-1, which has a Y68N mutation. 
The murine PD-1 – PD-L2 co-crystal shows that although the shorter Asn68 side chain cannot hydrogen 
bond directly to Asn66 or Asp111, it hydrogen bonds to a crystal water molecule that forms the same 
hydrogen bond network as Tyr68 (Figure 2.5c). MDs of a human Y68N PD-1 mutant and the GDG peptide 
suggest a functional equivalence of Asn68 to Tyr68: the Asn68 side chain spontaneously recruits a stable 
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water to the co-crystal position that then opens Asn66 via a specific hydrogen bond network analogous 
to that formed by Tyr68 (Figure 2.5e). 
 
2.2.4 ADY/GDY ligand motifs stabilize distinct bound-like states for PD-L1/2.  
 
 
While GDG MDs show an open Asn66 (Figure 2.4a) that exposes a hydrophobic surface, this surface 
remains flexible and fluctuates between a deep open cavity and closed shallow patch (Figure 2.4b). 
Contrary to the GGG MDs that exhibited open-closed fluctuations of Asn66 (Figure 2.4a), the pocket 
instability observed in GDG MDs is caused by open-closed fluctuations of PD-1 residue Ile126 (Figure 2.4c). 
In contrast, MDs show that the GDY peptide stabilizes the open states of both Asn66 and Ile126 and 
maintains the open hydrophobic interface cavity seen in the PD-L2 bound-like state of PD-1 (Figure 
2.4b,c,d). Comparison of the GDG and GDY MDs reveal that the Tyr side chain serves as a ‘wedge’ that 
stabilizes the flexible loop surrounding Ile134 into a bound-like configuration that is observed in both the 
PD-L1 and PD-L2 co-crystal structures (Figure 2.6). In the presence of the GDY peptide, the bound-like 
Ile134 makes a hydrophobic contact with the long arm of Ile126, which pulls the latter residue out of the 
pocket and stabilizes its open state (Figure 2.15). 
 
Although the PD-L1 interface exhibits the GDY scaffold, Ile126 is closed in the PD-L1-specific ECBL state, 
suggesting that an additional ligand motif not contained in the GDY scaffold is responsible for closing the 
pocket. MDs with an ADY peptide that mimics Ala121 show that the extra Cβ carbon of the Ala side chain 
out-competes Ile134 for the long arm of Ile126, stabilizing its closed state (Figure 2.4c,e). Interestingly, 
MDs with GDG and ADG peptides both show similarly unstable open-closed fluctuation of Ile126 (see 
Figure 2.7 below), which suggests that the effect of the Ala121 Cβ carbon on Ile126 dynamics only emerges 
in the presence of the anchor Tyr123/112. Thus, in addition to facilitating molecular recognition, 
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stabilization of the Ile134 loop by the burial of Tyr123/112 is shown to enable ligand-specific induced fit 
responses by the PD-1 interface. 
 
 
 
Figure 2.6. Stabilization of bound-like Ile134 by conserved tyrosine (Y) anchor. Average and standard 
deviation heavy atom RMSD of PD-1 Ile134 to the PD-L1/2 bound-like state (measured from human PD-1 
– PD-L1 cocrystal, 4ZQK; Ile134 has < 0.2 Å heavy atom RMSD between 4ZQK and the PD-L2 cocrystal 
3BP5). Data is shown for three 200ns replicate simulations for each system, including apo human PD-1 
and PD-1 interacting with various peptides.  
 
Although the PD-L1 interface exhibits the GDY scaffold, Ile126 is closed in the PD-L1-specific ECBL state, 
suggesting that an additional ligand motif not contained in the GDY scaffold is responsible for closing the 
pocket. MDs with an ADY peptide that mimics Ala121 show that the extra Cβ carbon of the Ala side chain 
out-competes Ile134 for the long arm of Ile126, stabilizing its closed state (Figure 2.4c,e). Interestingly, 
MDs with GDG and ADG peptides both show similarly unstable open-closed fluctuation of Ile126 (see 
Figure 2.7 below), which suggests that the effect of the Ala121 Cβ carbon on Ile126 dynamics only emerges 
in the presence of the anchor Tyr123/112. Thus, in addition to facilitating molecular recognition, 
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stabilization of the Ile134 loop by the burial of Tyr123/112 is shown to enable ligand-specific induced fit 
responses by the PD-1 interface. 
 
 
Figure 2.7. Downhill binding pathways of PD-1 triggers of induced fit for each cognate ligand. Points on 
the plot represent average and standard deviation equilibrium free energy differences (from three 
replicate simulations) between the open and closed states of receptor residues Asn66 and Ile126 for apo 
PD-1 and PD-1 interacting with nine distinct ligand-mimicking peptides. The corresponding numerical 
values can be found in Table 2.2. Yellow and orange lines represent the ligand-specific induced fit binding 
pathways from the apo receptor ensemble to the PD-L1 and PD-L2 bound-like ensembles, respectively. 
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Table 2.2. Free energy difference between the non-bound-like and bound-like states of PD-1 interface 
residues Asn66 and Ile126 in various systems. Listed values show the average and standard deviation of ∆𝐺#$ (from three replicate simulations) for Asn66 and Ile126 in the different PD-1 systems. Since the 
bound-like state of Ile126 is closed when PD-L1 – bound and open when PD-L2 - bound, the ∆𝐺#$ values 
for this residue take opposite signs. The trivial relationship between ∆𝐺#$ and ∆𝐺'&*+ are indicated for 
each column. Values shown are in units of kBT, with T = 300 K. 
 
 
 PD-L1 / PD-L2 PD-L1 PD-L2 
PD-1 
Simulation 
∆𝐆𝐁𝐋(𝐀𝐬𝐧𝟔𝟔)  ∆𝐺'&*+(𝐴𝑠𝑛66) 
(kBT)  
∆𝑮𝑩𝑳(𝑰𝒍𝒆𝟏𝟐𝟔	)  −∆𝐺'&*+(𝐼𝑙𝑒126) 
(kBT) 
∆𝑮𝑩𝑳(𝑰𝒍𝒆𝟏𝟐𝟔)  ∆𝐺'&*+(𝐼𝑙𝑒126) 
(kBT) 
apo (∆𝐺#$%&') 3.6 ± 0.60 4.4 ± 1.2 -4.4 ± 1.2 
Y (∆𝐺#$H ) 1.7 ± 0.61 1.3 ± 0.3 -1.3 ± 0.3 
DY (∆𝐺#$IH) 0.11 ± 0.44 -0.21 ± 0.74 0.21 ± 0.74 
GGG (∆𝐺#$JJJ) -0.28 ± 0.52 0.7 ± 0.8 -0.7 ± 0.8 
GGY (∆𝐺#$JJH) 0.02 ± 0.17 0.58 ± 0.22 -0.58 ± 0.22 
GDG (∆𝐺#$JIJ) -2.3 ± 0.32 -0.46 ± 0.36 0.46 ± 0.36 
ADG (∆𝐺#$KIJ) -3.0 ± 0.45 0.35 ± 0.60 -0.35 ± 0.60 
GDY (∆𝐺#$JIH) -3.0 ± 0.7 2.3 ± 0.72 -2.3 ± 0.72 
ADY (∆𝐺#$KIH) -2.7 ± 0.44 -2.0 ± 0.36 2.0 ± 0.36 
mGDV (∆𝐺#$LJIM) -3.0 ± 0.47 -1.8 ± 0.48 1.8 ± 0.48 
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2.2.5 PD-L1/2 triggers ADY/GDY produce energetically downhill induced fit binding pathways.  
 
We applied Maxwell-Boltzmann statistics to our peptide simulations (see Chapter 2.4 Methods) to 
quantify the role played by each trigger in the structural transitions at the PD-1 interface. We evaluate ∆𝐺'&*+ , i.e., the free energy differences between the open and closed states of Asn66/Ile126 for PD-1 in 
isolation and PD-1 interacting with nine different peptides representing distinct PD-L1/2 interface motifs 
(Figure 2.3, Table 2.2; note that ∆𝐺'&*+  and ∆𝐺#$ are trivially related). These ∆𝐺'&*+  values are plotted 
in Figure 2.7. Remarkably, the ADY and GDY motifs respectively shift the ratio of our predefined bound-
like to non-bound-like states from 1 : 44 ± 24 (based on ∆𝐺'&*+%&' (𝐴𝑠𝑛66)) to 7.4 ± 2.8 : 1 for the PD-L1 
bound-like state (based on ∆𝐺'&*+KIH (𝐼𝑙𝑒126)) and 12 ± 9.6 : 1 for the PD-L2 bound-like state (based on ∆𝐺'&*+JIH (𝐼𝑙𝑒126)). More importantly, we show that each triggering contact monotonically lowers the 
relative free energy of ligand-specific bound-like states starting from no contacts (apo), to the first, 
conserved contact with the anchor (Y), to the second, conserved contact with Asp122/111 (DY), to the 
final, unconserved contact with the backbone O of A/G in the complete triggering motifs (ADY/GDY) 
(Figure 2.7). The fact that these downhill binding pathways do not encounter energy barriers strongly 
suggests that the PD-1 binding mechanism is primarily one of induced fit (see Figure 2.1). 
 
In the apo simulation Asn66 is closed (∆𝐺'&*+%&' (𝐴𝑠𝑛66) ≈ 	3.6	𝑘#𝑇), repelling Ile126 into an open 
conformation (∆𝐺'&*+%&' (𝐼𝑙𝑒126) ≈ 	−4.4	𝑘#𝑇). Docking of the Tyr anchor (Y) and formation of the 
encounter complex destabilizes the non-bound-like apo PD-1 interface, causing increased open-closed 
fluctuations in both Asn66 and Ile126. The subsequent docking of Asp122/111 (DY) allows Tyr68 to 
compete with Lys78 to form one hydrogen bond with Asn66, causing it to swap back and forth between 
open and closed (∆𝐺'&*+IH (𝐴𝑠𝑛66) ≈ 	0). Fluctuations of Asn66 correlate with simultaneous fluctuations 
of Ile126 (∆𝐺'&*+IH (𝐼𝑙𝑒126) ≈ 	0). Adding the adjacent Ala121/Trp110 backbone from PD-L1/2 (ADY/GDY) 
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provides the second hydrogen bond for the NH2 of Asn66 that fully stabilizes its open state 
(∆𝐺'&*+JIH/KIH(𝐴𝑠𝑛66) ≈ 	−3.0	𝑘#𝑇). With Asn66 open, the Cβ atom of Ala121 modulates Ile126 dynamics. 
When present (ADY), the Cβ hydrophobically recruits Ile126 into the closed pocket state 
(∆𝐺'&*+KIH (𝐼𝑙𝑒126) ≈ 	2.0	𝑘#𝑇). Without Cβ (GDY), Ile126 remains open (∆𝐺'&*+JIH (𝐼𝑙𝑒126) ≈ 	−2.3	𝑘#𝑇).  
 
Our ∆𝐺'&*+  calculations also quantify the critical role of the anchor residue Tyr123/112 in ensuring the 
ligand specificity of PD-1 interface deformations. This is demonstrated by the fact that GDY and ADY 
peptides impose clear differential influence on the dominant rotamer state of Ile126, while for both GDG 
and ADG, Ile126 fluctuates about evenly between the open and closed state (∆𝐺'&*+JIJ/KIJ(𝐼𝑙𝑒126) ≈ 0) 
(Figure 2.7). 
 
2.2.6 Encounter complex simulations suggest chronology of induced fit triggering interactions.   
 
We ran MDs of the PD-L1/2 encounter complexes starting from docked poses of apo PD-1 and the 
interacting domains of PD-L1/2 that anchored Tyr123/Y112 (see Chapter 2.4 Methods). Encounter 
complex MDs recapitulated the triggering mechanisms we identified in our peptide simulations and their 
resulting PD-1 interface transitions from the ECNBL to the ligand-specific ECBL states. The chronology for 
these interactions (Table 2.3) is the same for both ligands. Consistently, the first interaction to take place 
after docking the conserved anchor is the formation of the hydrogen bond between receptor residue 
Tyr68 and ligand residue Asp122/111. This is followed by stabilization of Asn66 in the open pocket state 
via hydrogen bonds with neighboring Tyr68 and the ligand Ala121/Trp110 backbone. The Ala121/Trp110 
side chains then proceed to stabilize a closed/open hydrophobic pocket. Note that the Trp in the WDY 
motif of PD-L2 readily fills the hydrophobic pocket as the XDY motif latches and opens Asn66 (Figure 2.8). 
Consistent with a downhill free energy induced fit mechanism, the realization of these four contacts takes 
less than 10 ns total. On a longer timescale, encounter complex simulations demonstrate the formation 
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of secondary hydrogen bonds at the interface periphery that are also observed in co-crystal structures of 
human and murine PD-1. These secondary hydrogen bonds, including the bond from PD-1 Lys78 to PD-
L1/2 Phe19/21 and from Gln75 to Arg125/Tyr114 (Figure 2.9), were consistently observed to form 
approximately 10 nanoseconds after the aforementioned Asn66 and Tyr68 hydrogen bonds (Table 2.3), 
suggesting that ECBL contacts shaped by the triggers of induced fit are enough to drive the subsequent 
transition to the HAC. 
 
Table 2.3. Chronology of the formation of intermolecular interactions between PD-1 and PD-L1/2 in 
encounter complex simulations. Listed values show the average and standard deviation time to formation 
(from three replicate simulations) of various inter- and intra-molecular hydrogen bonds following the 
burial of the ligand anchor and formation of the key Tyr68–Asp122/111 hydrogen bond. 
 
 Δt (ns) after Tyr68 – Asp122/111  
hydrogen bond formation 
Hydrogen Bond PD-1 - PD-L1 
Encounter Complex 
PD-1 - PD-L2 
Encounter Complex 
Asn66 – Ala121/Trp110 6.3 ± 2.9 6.7 ± 7.2 
Asn66 – Tyr68 5.0 ± 1.7 8.3 ± 7.5 
Gln75 – Arg125/Tyr114 15 ± 7.8 17 ± 11 
Lys79 – Phe19/21 13 ± 15 15 ± 20 
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Figure 2.8. Modulation of the PD-1 interface binding cavity in encounter complex simulations with PD-
L1 and PD-L2. Plot shoes the (rolling average) number of atoms in the bound-like Trp110 side chain 
reference that are occluded by the PD-1 interface throughout encounter complex simulations with PD-
L1/2 (see Chapter 2.4 Methods for full details of how occlusion is calculated). Both encounter complexes 
begin with a closed Trp110 pocket, as this is the dominant state of apo PD-1. The PD-L2 trigger then 
stabilizes the hydrophobic cavity (no overlap), while the PD-L1 trigger stabilizes the hydrophobic patch 
(significant overlap). 
 
 
Figure 2.9. Secondary, non-triggering contacts in PD-1 encounter complexes. Specific hydrogen bonds 
observed in the PD-1 – PD-L1 (a) [20] and PD-1 – PD-L2 (b) [21] cocrystal structures. In simulation these 
contacts form approximately 10 ns after triggering interactions and their resulting induced fit 
deformations of the receptor (Table 3). Note also that the conserved Tyr123/112 anchor forms identical 
hydrogen bonds with Glu136 in the PD-L1 – and PD-L2 – bound states.     
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2.2.7 PD-1 – targeting antibody validates the critical role of Asn66 and suggests an anchor-
independent binding mechanism with closed Ile126 and Ile134.  
 
Recently, two FDA-approved PD-1 –  targeting antibodies have emerged as part of a new generation of 
anti-cancer immune checkpoint inhibitors. Published crystal structures of one of these antibodies, 
pembrolizumab, bound to extracellular PD-1 show a hydrophobic receptor binding surface that overlaps 
that which binds PD-L1/2 (Figure 2.10b) [40-42]. Comparison of the pembrolizumab – PD-1 interface to 
the PD-L1 – PD-1 interface using the FastContact server [43] highlights several differences in the main 
contacts that characterize the two binding modes (Figure 2.10a, Tables 2.4, 2.5). Remarkably, the 
pembrolizumab-bound crystal structures reveal that the antibody stabilizes the same open state of 
Asn66 as PD-L1/2 using an analogous hydrogen bond network (Figure 2.10c). The fact that this antibody, 
designed via a distinct evolutionary pathway, shares PD-L1/2’s mechanism for opening Asn66 and 
revealing a hydrophobic binding surface (Figure 2.2a,b,c, Figure 2.10b) underscores the role of this 
specific interaction in PD-1 interface remodeling.  
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Figure 2.10. Pembrolizumab – bound PD-1 interface resembles PD-L1 – bound interface with a closed 
Ile134. (a) Alignment of crystal structures of the pembrolizumab antibody (Ab) [40] and PD-L1 [20] binding 
modes, showing distinct but partially overlapping binding interfaces on PD-1. The light chain of the Ab is 
shown in magenta and the heavy chain is shown in purple.  (b) Detailed comparison of the aligned Ab – 
bound (grey) and PD-L1 – bound (green) PD-1 interfaces. Most receptor interface residues exhibit near-
identical conformations, except Ile134 which is open when bound to PD-L1 but closed when bound to 
pembrolizumab. Heavy chain Ab interface residues are shown in purple. (c) Detail of the Ab – PD-1 
interface, highlighting the hydrogen bond (hydrogen bond) network that stabilizes the open state of 
Asn66. This hydrogen bond network is functionally analogous to those observed in the PD-L1 and PD-L2 – 
bound cocrystals (Figure 2.5), although the OD1 and ND2 atoms of Asn66 are flipped. (d) Simulation 
snapshot of human PD-1 interacting with the mGDV motif from Bristol-Myers Squibb macrocyclic PD-1 
inhibitor, highlighting the canonical hydrogen bond network that opens Asn66.    
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Table 2.4. Top 5 PD-1 residues contributing to electrostatic energy when binding to PD-L1 and 
pembrolizumab. Binding energies were calculated using the FastContact web server [43] and cocrystal 
structures of PD-1 bound to PD-L1 [20] and pembrolizumab [40]. 
PD-L1 – bound Pembrolizumab – bound 
Residue Energy (kcal/mol) Residue Energy (kcal/mol) 
Glu136 1 -11.531 Asp85 3 -8.367 
Asp77 -5.073 Ser87 -3.629 
Lys78 2 -4.266 Asp77 -2.417 
Gln75 -4.027 Tyr68 -2.156 
Glu84 -3.119 Glu136 -2.096 
1 The E136A mutation abolishes binding of PD-1 to PD-L1 and greatly reduces binding to PD-L2 [21]. 
2 The K78A mutation abolishes binding of PD-1 to PD-L1 and greatly reduces binding to PD-L2 [21]. 
3 The D85G mutation abolishes binding of PD-1 to pembrolizumab [42]. 
 
 
Table 2.5. Top 5 PD-1 residues contributing to desolvation energy when binding to PD-L1 and 
pembrolizumab. Binding energies were calculated using the FastContact web server [43] and cocrystal 
structures of PD-1 bound to PD-L1 [20] and pembrolizumab [40]. 
PD-L1 – bound Pembrolizumab – bound 
Residue Energy (kcal/mol) Residue Energy (kcal/mol) 
Ile126 1 -1.853 Leu128 2 -2.886 
Leu128 2 -1.673 Pro89 -2.486 
Ile134 3 -1.361 Val64 -1.721 
Val64 -0.463 Pro130 -1.586 
Ala132 -0.37 Pro83 -1.131 
1 The I126A mutation greatly reduces binding of PD-1 to both PD-L1 and PD-L2 [21]. 
2 The L128A mutation abolishes binding of PD-1 to PD-L1 and partially reduces binding to PD-L2 [21]. 
3 The I134A mutation abolishes binding of PD-1 t oPD-L1  and greatly reduces binding to PD-L2 [21]. 
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Although pembrolizumab’s interaction with Asn66 mimics the native-like contacts of PD-L1/2, the 
antibody-bound receptor exhibits a novel configuration of Ile134, with both Ile126 and Ile134 in inward-
flipped, ‘closed’ states (Figure 2.10b). The result is a large hydrophobic surface where, like in the PD-L1 – 
bound state, the closed Ile126 occludes the Trp110 binding pocket, but where, unlike the PD-L1/2 – bound 
states, a closed Ile134 partially fills the Tyr/123/112 anchor cavity. In fact, pembrolizumab has no anchor 
analog. Instead, the Arg102 side chain extends along the PD-1 interface such that the CZ carbon overlaps 
the Cg position of Tyr123/112 (Figure 2.18), and the NH1/2 groups hydrogen bond to a crystal water above 
the receptor interface (Figure 2.10b). In this configuration, the hydrophobic carbon chain of Arg102 forms 
a ‘cap’ above the closed Ile126 and Ile134, desolvating their hydrophobic interactions with each other and 
the neighboring Gly124 and stabilizing a flat hydrophobic surface (Figure 2.10b).  
 
A similar closed conformation of Ile134 is observed in our MDs of PD-1 interacting with the GDG peptide 
(Figure 2.15). This is unsurprising: like pembrolizumab, the GDG peptide has the necessary machinery to 
trigger the opening of Asn66, but lacks an anchor ‘wedge’ that prevents the resulting inward collapse of 
Ile134. Results of the GDG MDs thus rationalize the pembrolizumab binding mode and suggest an anchor-
independent induced fit PD-1 binding pathway: one in which the antibody opens Asn66 using the 
canonical hydrogen bond network and stabilizes the resulting flat hydrophobic interface by ‘capping’ the 
closed states of Ile126/134 with the carbon chain of Arg102. 
 
2.2.8 Can molecular triggers be exploited to drug PD-1?  
 
Although two PD-1 targeting antibodies already exist on the market, there are no small-molecule PD-1 
inhibitors in clinical trial, despite the enormous interest in this blockbuster immunotherapy target [30-
32]. Given that ligand binding sites tend to be concave [33, 34] and largely hydrophobic [35], the 
undruggability of PD-1 might be due to the closed Asn66 and the resulting flat polar interface in the apo 
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form (Figure 2.2a). However, the highly specific hydrogen bond network presented by PD-L1/2 and 
pembrolizumab strongly suggests a path to open Asn66 and transform the hard to drug hydrophilic patch 
into a hydrophobic one. Interestingly, Brystol-Myers-Squibb recently patented a 1.03 nM macrocyclic 
inhibitor of the PD-1 – PD-L1 interaction [44]. Although no mechanism of action has been described, the 
macrocycle includes a peptidic mGDV motif that is structurally similar to the aforementioned ADY induced 
fit trigger, with an N-methylated Gly and an Asp side chain that resemble PD-L1’s Ala121 and Asp122, 
respectively (Figure 2.18, Figure 2.19). This alignment puts the mGDV motif’s short Val side chain at the 
position of the much longer Tyr123 anchor, where it aligns with the C∆ side chain carbon of pembrolizumab 
residue Arg112 (Figure 2.18).  
 
Given the resemblance of the mGDV motif to the interface residues of both PD-L1 and pembrolizumab, 
we used our MDs method to evaluate whether this motif was capable of remodeling the apo, non-bound-
like PD-1 interface into a bound-like state. We observed that mGDV opened Asn66 using a native-like 
hydrogen bond network analogous to those seen in previous simulations (Figure 2.5, 2.7, 2.10d). However, 
Ile126 and Ile134 dynamics mirrored those seen in the pembrolizumab cocrystal, with both sidechains 
favoring inward-flipped ‘closed’ configurations (Figure 2.11).  Simulation trajectories showed that the 
short Val side chain of the mGDV motif, unlike the cognate Tyr123/112 anchors, did not penetrate deep 
enough into the PD-1 interface to be a ‘wedge’ stabilizing an open Ile134. Instead, like the carbon chain 
of pembrolizumab residue Arg102, the Val ‘capped’ stable hydrophobic interactions between a closed 
Ile134, a closed Ile126, and the neighboring Gly124. 
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Figure 2.11. Macrocyclic mGDV motif induces structural changes in the PD-1 interface towards the 
pembrolizumab – bound state. Heat maps show the distributions of PD-1’s Ile126 and Ile134 X1 rotamer 
angles in MDs of the receptor interacting with the ADY PD-L1 trigger (left), the BMS macrocycle mGDV 
motif (center), and the GDV peptide. Data for each ligand was gathered from three distinct 200ns 
simulations. White dots on the plots indicate the rotamer angles of the same two residues in the 
pembrolizumab (Ab) – bound [40] and PD-L1 – bound [20] cocrystal structures. 
 
Our GDG, ADG, GDY, and ADY simulations demonstrated that precise regulation of the closed/open states 
Ile126 via the Ala121 Cß is realized only when the Tyr123/112 anchor is buried (Figure 2.7). Thus, given 
that mGDV lacks an anchor, a natural question to ask is whether a Ile126 would be opened by a GDV 
peptide without the N-methyl group. Interestingly, MDs of PD-1 interacting with a GDV peptide revealed 
identical Ile126 and Ile134 dynamics to mGDV simulations (Figure 2.11), indicating that the N-methyl 
group was not recruiting Ile126 into the closed state in the style of Ala121 Cß. These results help to further 
illuminate the role of the conserved anchor Tyr123/112, which in its absence does not wedge Ile134 into 
the open state, disabling the capability of PD-1 to stabilize an open Ile126 and form a hydrophobic cavity 
at that site. 
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Compared to GDG simulations in which Ile126 fluctuated between open and closed (Figure 2.4b,c), in GDV 
simulations it remained closed, suggesting a stabilizing role for the Val side chain. The overlap of (m)GDV’s 
Val with the carbon chain of pembrolizumab’s Arg102 (Figure 2.18) and the similarity between the 
(m)GDV-induced PD-1 interface and the pembrolizumab – bound interface supports the ‘capping’ role of 
Arg102 in stabilizing the flat hydrophobic surface of PD-1. This mechanism is also consistent with models 
of macrocycle conformations generated by Balloon [45] docked to PD-1, which readily identify poses that 
align the mGDV motif to corresponding PD-L1 and pembrolizumab interface residues (Figure 2.18, Figure 
2.19), rationalizing the potency and specificity of the compound. 
 
 
 
2.3 DISCUSSION 
 
2.3.1 Induced fit motif XDY shared by PD-1 ligands modulates the flexible PD-1 binding interface from 
hydrophilic to hydrophobic.  
 
Our studies show that apo PD-1 does not sample bound-like hydrophobic interface conformations, but 
instead presents a non-bound-like hydrophilic patch around Asn66 at the core of its binding interface 
(Figure 2.2). By mapping the effect of specific ligand contacts on the apo PD-1 interface, we identify a 
highly-conserved subset of PD-L1/2 motifs responsible for coordinating Asn66 and triggering the 
transition from the hydrophilic to hydrophobic interface. Namely, Asp122/111 and the backbone O of PD-
L1/2 Ala121/Trp110 form a robust, four-membered hydrogen bond network with Tyr68 and Asn66 that 
neutralizes the latter residue into a bound-like open state. Simultaneously, the conserved anchor 
Tyr123/112 stabilizes Ile134 into a bound-like state that, with Asn66 open, creates a hydrophobic surface 
that fluctuates between a patch and a cavity modulated by Ile126. These three linear ligand motifs (XDY), 
shared by both PD-L1/2, comprise the molecular key that unlocks the promiscuity of PD-1 by revealing a 
flexible hydrophobic binding surface (Figure 2.4). 
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2.3.2 A single carbon atom difference can shift the hydrophobic PD-1 binding surface from a stable 
patch to a stable cavity.  
 
With XDY triggering the transition to the flexible hydrophobic surface, specificity towards the two PD-1 
ligands is actualized by the formation of the hydrophobic patch when binding PD-L1 vs. the formation of 
hydrophobic cavity when binding PD-L2. These two states can be distinguished by the conformation of 
Ile126 (Figure 2.2e). For PD-L1, we show that the ADY motif is sufficient to stabilize the hydrophobic patch 
(Figure 2.4c). Specifically, the Ala121 Cβ atom, which does not overlap with PD-1 apo NMR structures 
(Figure 2.2d), recruits Ile126 into the closed (patch) state. On the other hand, in the absence of Cβ, the 
GDY trigger stabilizes the open state of Ile126, producing a large hydrophobic interface cavity consistent 
with the pocket that buries PD-L2 Trp110. Note that the Trp in the WDY motif of PD-L2 readily fills the 
hydrophobic pocket as the XDY motif latches and opens Asn66 (Figure 2.8). 
 
2.3.3 Bound-like XDY residues and molecular recognition.  
 
The pre-arrangement of PD-L1/2 motifs XDY in bound-like conformations in the absence of the receptor 
is important for efficient ligand recognition and binding. Docking studies and peptide MDs highlight a 
critical role for the conserved Tyr123/112 anchor both in both molecular recognition and in modulating 
Ile134 during induced fit, both of which require the Tyr side chain to maintain a stable bound-like rotamer. 
Furthermore, simulations demonstrate that peptides such as GDG, mGDV, and GDV, which either lack or 
have a modified anchor analogue, cannot stabilize an open state of Ile126, highlighting an allosteric role 
for Tyr123/112 in splitting the PD-1 induced fit binding pathway.  
 
Several anchors substitutes were tested in simulation starting in bound-like configurations similar to the 
cognate Tyr112/123. These MDs produced three broad types of PD-1 interface dynamics (Figure 2.17): (1) 
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aromatic substitutions XDF and XDW stabilized either an open (X=G) or closed (X=A) pocket like the 
cognate XDY motif. (2) Polar substitutions XDH, XDR, and XDK were not accommodated in the hydrophobic 
anchor pocket and their side chains laid along the receptor surface, consistent with pembrolizumab’s 
bound Arg102 (Figure 2.10b), producing a closed pocket like that of (m)GDV. (3) XDG or XDA resulted in 
open-closed fluctuations of both Ile134 and Ile126 (Figure 2.4b,c). These observations suggest that certain 
anchor mutations are tolerated by PD-1 and are consistent with mutagenesis studies showing that the 
Y112A PD-L2 point mutation slightly reduces, but does not abolish, binding to PD-1 [21]. However, the 
observed conservation of Tyr123/112 in mammalian species [21] might suggest specific kinetic constraints 
on ligand recognition arising from hydrophobic contacts with Ile134 and the hydrogen bond with Glu136 
(Figure 2.9), which are not shared by other sidechains.  
 
In addition to the anchor residue, our peptide MDs also suggest an essential role for the conserved 
Asp122/111 in erecting a stable hydrogen bond network that opens PD-1 Asn66, which can only be 
achieved by a bound-like Asp side chain. The primacy of these intermolecular interactions to PD-1 binding 
is reinforced by our MDs of apo PD-L1/2, which reveal that Tyr123/112 and Asp122/111 all remain in 
bound-like conformations in the absence of the receptor, primed to interact immediately upon interface 
association. Equally important is the fact that apo PD-1 structures all accommodate (i.e. do not block) any 
of contacts of the XDY scaffold, ensuring a rapid recognition process that facilitates subsequent induced 
fit transitions. 
 
2.3.4 Downhill binding pathways strongly suggest an induced fit binding mechanism.  
 
Our MDs demonstrate that the set of consecutive intermolecular interactions triggered by ADY and GDY 
peptides lead to energetically downhill binding pathways with no opposing energy barriers. These 
pathways strongly suggest that PD-1 occurs mostly by induced fit (Figure 2.1). Specifically, simulations and 
 34 
estimated ∆𝐺'&*+  values show that apoBL states of PD-1 are rare, which undermines a conformational 
selection mechanism. On the other hand, ligand-specific triggers are shown to efficiently shift the PD-1 
interface conformational ensemble from a non-bound-like : bound-like ratio of roughly 44 : 1 (in the apo 
ensemble) to roughly 1 : 7 (in the encounter complex ensemble) (Figure 2.7). Unconstrained MDs of PD-
L1/2 encounter complexes show that the geometry and chronology of triggering contacts is highly 
optimized, driving the transition from the non-bound-like to the bound-like states in less than 10 ns. This 
time scale promotes rapid recognition and ensures fast activation of this important T-cell checkpoint. 
 
2.3.5 Two step binding pathway of PD-1 reveals a simple mechanism for selective promiscuity. 
 
 Although regulatory proteins are promiscuous in that they bind multiple targets, they must also be 
specific so as to limit binding to just those targets. Our analysis of the binding mechanism to PD-1 reveals 
how these two seemingly contradictory requirements can be simultaneously achieved. Here, we show 
that apo PD-1 samples an ensemble of non-bound-like conformations that present an obstructive Asn66 
on its interface, which likely prevents non-specific binding. The apo PDL1/2 interfaces feature a conserved, 
bound-like, XDY binding motif that holds the key to opening Asn66 and forming a flexible hydrophobic 
surface, which completes the first binding step. In the second step, the ligands then attune the flexible 
interface via specificity-determinant contacts (X=A for PD-L1, X=W for PD-L2) that modulate Ile126, 
splitting the binding pathway and stabilizing either a hydrophobic patch or a binding pocket (Figures 2.2, 
2.4, 2.7). The key structural properties in this pathway are: (a) a flexible, non-bound-like apo receptor 
interface ensemble that presents an unfavorable binding surface, (b) a core subset of shared ligand 
binding motifs clustered about an anchor residue that latch the receptor interface but allow it to remain 
flexible, and (e) ligand-specific motifs that split the binding pathway by stabilizing different conformations 
of the flexible interface.  
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2.3.6 Molecular triggers could be exploited to design small-molecule PD-1 antagonists.  
 
Bound cocrystal structures of the PD-1 – targeting antibody pembrolizumab reveal that it exploits an 
evolutionarily-designed induced fit trigger: the four-membered hydrogen bond network that opens Asn66 
and makes the receptor interface hydrophobic. This same principle can be applied to design smaller 
molecular weight PD-1 inhibitors. We have shown that the mGDV motif of the Brystol-Myers-Squibb PD-
1 inhibitor combines key pharmacophore features of both PD-L1 and pembrolizumab interfaces: the 
backbone O of the Gly resembles that of PD-L1’s Ala121, the Asp side chain resembles PD-L1’s Asp122, 
and the Val side chain resembles pembrolizumab’s Arg102. Simulations suggest that this structural 
resemblance produces functionally similar dynamics by displacing receptor residue Asn66 (Figure 2.10d) 
and stabilizing a bound-like, flat hydrophobic surface formed by closed Ile126 and Ile134 (Figure 2.7, 2.11). 
Docked conformations of the full inhibitor recapitulate most secondary native-like contacts in addition to 
the core triggering interactions (Figure 2.18, Figure 2.19). Taken together these results support the idea 
that nature’s mechanisms for modulating receptor surfaces might be exploited to design novel 
chemistries capable of transforming hard to drug targets into more druggable candidates. 
 
2.3.7 Selective promiscuity via induced fit offers potential advantages over conformational selection 
for multi-ligand regulatory proteins.  
 
Promiscuous regulatory proteins must optimize binding kinetics for multiple ligands by exploiting 
structural flexibility. Given nature’s general mechanisms for flexibility-mediated binding (Figure 2.1), 
specificity towards multiple ligands could, in principle, be conferred either through conformational 
selection, by evolving the receptor to intrinsically sample different ligand-specific apoBL states, or by 
induced fit, by evolving interface interactions that efficiently drive transitions to the ligand-specific ECBL 
states. If conformational selection is used to achieve multi-ligand specificity, the binding pathway flux will 
de facto be limited by ∆𝐺#$%&', the free energy difference between each ligand-specific bound-like states 
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and other states in the apo ensemble. In this scenario, a natural bottleneck would emerge as an increasing 
number of ligands would lead to lower association rates. 
 
On the other hand, if selective promiscuity is conferred through induced fit, binding pathway flux will not 
depend on the fractional populations of apo ensemble microstates, but instead will be determined by the 
ligand-specific triggering mechanisms. We show here that induced fit can efficiently reshape the shallow 
polar interface of a flexible receptor into a hydrophobic interface amenable to binding multiple ligands by 
co-evolving a common set of intermolecular contacts. From an evolutionary perspective, this is an efficient 
approach to spawning novel protein interactions, since these core contacts can be designed just once. 
Selectivity to novel ligands can then be achieved by evolving relatively small sequence modifications 
around these core contacts. Perhaps more importantly, we note that contrary to conformational 
selection, the induced fit approach to selective promiscuity is in principle not limited by the total number 
of ligands. 
 
It is interesting to note that many well-characterized eukaryotic regulatory domains [46] bind to several 
linear binding sequences that share common motifs around an anchor residue and differ in other nearby 
regions. This trend suggests that the selective promiscuity via induced fit mechanism proposed here for 
PD-1 might apply elsewhere in nature. This possibility is currently being studied by analyzing the triggers 
of induced fit in other systems. 
 
 
 
2.4 METHODS 
 
2.4.1 Initial protein structures used in simulations.  
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Molecular dynamics simulations (MDs) of the extracellular domain of PD-1 were run in triplicate using the 
first three solution NMR structures of apo human PD-1 (PDB ID: 2M2D [19]). Before simulating specific 
receptor - ligand interactions, MDs of apo PD-1 were evaluated to ensure that the resultant dynamics are 
consistent with the experimentally derived apo NMR ensemble. As shown in Figure 2.12, apo MDs stabilize 
within about 2.0 Å backbone RMSD of their respective NMR starting points, suggesting that we can 
successfully sample native-like unbound states. 
 
Available co-crystal structures of human PD-1 / human PD-L1 (PDB ID: 4ZQK [20]), murine PD-1 / human 
PD-L1 (PDB ID: 3BIK [22]) and murine PD-1 / murine PD-L2 (PDB ID: 3BP5 [21]) complexes were used as 
templates for placement of peptides in bound-like loci at the receptor interface, and the dynamics of the 
PD-1 binding interface in response to interactions with different structural motifs on the ligands were 
analyzed. We focus on interactions relevant for the opening and closing of the pocket around Asn66. 
Based on co-crystals, we noticed that the core interacting residues of PD-L1 (Ala121, Asp122, Tyr123) and 
the homologous residues on PD-L2 (Trp110, Asp111, Tyr112) form critical hydrogen bonds (hydrogen 
bonds) shaping this pocket. Thus, to dissect the contribution of each contact, we simulate the effects of 
the receptor interacting with a diverse set of peptide derivatives of these specific ligand residues. 
 
 
Figure 2.12: Stability of apo PD-1 simulations. Backbone RMSD of apo PD-1 to the first three NMR 
models (shown in blue, red, and yellow, respectively). Data is shown for six simulations: two replicates 
(a,b) starting from each of the first three NMR models (1,2,3).    
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2.4.2 Peptide ligand mimics used in simulations.  
 
 
Ten distinct PD-1 systems were simulated in order to dissect the ligand groups that trigger induced fit 
interface deformations on the receptor. These systems included the apo receptor in isolation and in 
complex with nine different peptides that mimic cognate ligand backbone and side chain interactions with 
the receptor (Figure 2.3): the anchor residue Tyr, the backbone peptide GGG, five peptides to probe role 
of ligand side chain contacts DY, GGY, GDG, ADG, GDY, the PD-L1 peptide ADY, and the mGDV peptide, 
which mimics a patented PD-1 inhibitor.  
 
2.4.3 Simulating PD-1 – peptide interactions.  
 
To generate initial structures for our receptor-peptide MDs, NMR models 1-3 of the human PD-1 were 
backbone aligned to the murine receptor co-crystal [22] and peptides were modeled after the 
corresponding human PD-L1 interface residues Ala121 – Tyr123, homologous to PD-L2 interface residues 
W110 - Tyr112. Systems are simulated for 200 ns, resulting in three replicate MDs per system (including 
the apo PD-1 system, which does not include any peptide), and receptor interface dynamics are compared 
across systems to identify the ligand motifs and interactions responsible for structural transitions towards 
the bound-like receptor state. Harmonic restraints (100.0 kcal/mol) on all heavy atoms of ligand-
mimicking peptides were used in simulation to prevent dissociation of the peptide from the receptor 
interface. 
 
In peptide MDs, harmonic restraints (100.0 kcal/mol) were also placed on backbone atoms of non-
interface PD-1 beta sheets residues 50-55, 80-81, 96-98, 106-109 and 120-122. These residues exhibit < 
0.35 Å backbone RMSD in the apo NMR ensemble, and previous studies have also shown that the 
conformational changes induced by ligand binding do not propagate through the major fold of PD-1 [19]. 
Hence, these restraints should not prevent our ability to sample the native-like binding dynamics of the 
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receptor interface in biological conditions. The resolved portion of the N-terminal tail of PD-1 (residues 
33-36), which in NMR models has < 0.65 Å backbone RMSD, was also restrained so as to limit artificial 
mobility that might result from the fact that residues 1-32 were missing from simulation. 
 
2.4.4 Encounter complex modeling and simulation.  
 
Human PD-1 – PD-L1 and PD-1 – PD-L2 encounter complexes were modeled and then simulated in 
triplicate to probe induced fit trajectories and determine the chronology of inter-molecular interactions 
and specific interface deformations. We modeled encounter complexes by rigid body docking the 
extracellular domain of the apo receptor and the Ig-like V-type domains of the apo ligands, allowing no 
structural overlaps. Docked models of PD-L1 had an average backbone RMSD of 5.7 ± 1.2 to the human 
PD-1 – PD-L1 cocrystal. Docked models of PD-L2 had an average backbone RMSD of 4.8 ± 1.8 to the murine 
PD-1 – PD-L2 cocrystal (no human cocrystal is currently available for the PD-1 – PD-L2 complex).  
 
Structural models of apo human PD-L1 and PD-L2 that we used when building encounter complexes were 
generated by simulating the ligands in solution for 400 ns, using a VMD [47] clustering plugin 
(https://github.com/luisico/clustering) to cluster frames by backbone RMSD using a 3 Å cutoff, and taking 
the centroid frame of the largest cluster for each ligand. The initial structure for the PD-L1 clustering MDs 
was taken as the structure of the bound human ligand from the co-crystal complex with murine PD-1 (PDB 
ID: 3BIK). As there are currently no available crystal structures of human PD-L2, a homology model was 
built as a starting point for the clustering simulation by manually mutating the bound structure of murine 
PD-L2 (PDB ID: 3BP5) and minimizing the resulting structure. We used the ClusPro protein-protein docking 
server [39] to dock the top apo PD-L1 and PD-L2 centroid structures from their respective MDs to the first 
three NMR structures of apo human PD-1 (all three receptor structures are non-bound-like). Three bound-
like candidate models for the PD-1 – PD-L1/2 encounter complexes that correctly anchored Tyr123/112 
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were chosen from the ClusPro output. We then simulated these encounter complexes for 400 ns to probe 
the dynamics of the induced fit binding pathway.  
 
2.4.5 Simulation parameters.  
 
We ran MDs using AMBER14’s [48] pmemd.cuda module [49] and the AMBER ff12SB force field. The cutoff 
for non-bonded interactions was set at 10 Å. Systems were simulated in an octahedral TIP3P water box 
with periodic boundary conditions and a 12 Å buffer around the solute. Cl- ions were added to the solvent 
to neutralize the charge of the systems. We minimized each system twice and then equilibrated them 
before beginning production runs. In the first minimization, solute atoms were held fixed through 500 
steps of steepest descent and 500 steps of conjugate gradient minimization. In the second minimization 
only the solute backbone atoms were restrained through 2000 steps of steepest descent and 3000 steps 
of conjugate gradient. After minimization, system temperatures were raised to 300 K over the course of 
a 200 ps constant volume simulation (with an integration step of 2 fs) during which the solute was fixed 
with weak (10.0 kcal/mol) restraints. Bonds involving hydrogens were held at constant length. For the 
production MDs, the 200 - 400 ns simulations were held at 300 K under constant pressure with the 
constraints as listed above for each system and an integration step size of 2 fs. 
 
2.4.6 Analysis tools. 
 
The PyMOL Molecular Graphics System v1.7.4.0 was used for structure preparation and analysis [50]. 
Trajectories were analyzed using VMDv1.9.2 [47] and the MDpocket software package v2.0 [51, 52] for 
cavity detection and volume / surface area measurement. Measurements of PD-1 binding pocket 
occlusion, shown in Figures 2.2d and 2.4d,e, were calculated from molecular dynamics simulations of PD-
1 using a Python script [46]. Briefly, the script takes a molecular dynamics trajectory and a set of static 
reference atoms and identifies which reference atoms are overlapped in each frame of the simulation. 
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Overlap occurs when any simulated atom crosses the “clash radius” of a reference atom, the clash radius 
being equal to the sum of the van der Waals radii of the two atoms. The output of the script is the 
fractional occlusion of each reference atom position, equal to the percentage of simulation frames in 
which that reference atom is overlapped by simulated atoms. This script was used to evaluate the extent 
to which the Trp110 and Tyr112/123 binding cavities are open in simulations of PD-1 interaction with 
various peptides, simulations of apo PD-1, and the apo NMR ensemble of PD-1. 
 
2.4.7 Relative free energies of bound-like versus non-bound-like interfaces.  
 
We classified PD-1 interface conformations using two binary order parameters that define whether 
interface residues Asn66 and Ile126 are in their ‘open’ or ‘closed’ rotamer states. These parameters are 
used to distinguish the non-bound-like interface, where Asn66 is closed and Ile126 is open, from the PD-
L1-specific bound-like state, where Asn66 is open and Ile126 is closed, and the PD-L2-specific bound-like 
state, where both Asn66 and Ile126 are open (Figure 2.2e). We estimated the energy differences ∆𝐺#$%&' 
and ∆𝐺#$() (Figure 2.1) using Maxewell-Boltzmann statistics by assessing the bound-like (BL) and non-
bound-like (NBL) state population distributions in the apo and encounter complex (EC) receptor 
ensembles: 
 
  
〈+WXYZ[/\]〉〈+_WXYZ[/\]〉 = 𝑒a∆bWXYZ[/\]cWd   (1) 
 
In the above equations, 〈𝑛#$%&'/()〉 and 〈𝑛e#$%&'/()〉 denote fractional equilibrium populations of the apo / 
encounter complex receptor ensembles in the bound-like and non-bound-like macrostates, and kBT is the 
product of the Boltzmann constant and temperature. We used MDs to generate the equilibrium 
ensembles of receptor conformations and analyzed the trajectories to calculate 〈𝑛#$/e#$%&'/() 〉 values. 
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MDs trajectories were analyzed as follows. Reference structures for the open and closed states of Asn66 
were defined using its side chain configuration in the first apo NMR model and PD-L1-bound human 
cocrystal, respectively (Asn66 has < 0.2 Å heavy atom RMSD between PD-L1 and PD-L2 cocrystals 4ZQK 
and 3BP5). Each frame of the MDs trajectory is labeled with the state to which the simulated Asn66 had 
the smaller side chain RMSD to the reference structure. Reference structures for the open and closed 
states of Ile126 were defined using its Χ1 rotamer angle in the murine PD-L2 and human PD-L1 
cocrystals, respectively, this angle being the main distinguishing feature between the two different 
ligand-bound interfaces (Figure 2.2e). Each frame of the MDs was labeled with the state to which the 
simulated Ile126 had the closest rotamer angle. The free energy changes of opening Asn66 and Ile126 
are calculated using eq. (1) and then compared across different simulations in order to identify triggers 
of interface deformations. 
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2.5 SUPPLEMENTARY FIGURES  
 
 
 
Figure 2.13. The cognate ligands of PD-1. Cocrystal structures of the extracellular domain of PD-1 bound 
to the Ig-like V-type domains of its two cognate ligands: (a) PD-L1 [20], and (b) PD-L2 [21]. Dashed lines 
indicate hydrogen bonds between the PD-L1/2 anchor and PD-1 residue Glu136. 
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Figure 2.14. Modulation of PD-1’s flexible interface cavity. Aligned structures of the apo (white) [19], PD-
L1 – bound (green) [20], and PD-L2 – bound (cyan) [21] PD-1 interfaces. Key PD-1 interface residues that 
line the cavity are shown as small sticks and labelled, with Asn66 and Ile126 shown as large sticks as in 
Figure 2.2c. The interface cavity volume of each structure is indicated by the transparent surface of 
matching color. PD-L2 interface residues Trp110 and the conserved Tyr112 anchor are shown as small 
orange sticks, for reference. The anchor pocket is unstructured in all three receptor states, but only the 
PD-L2 bound state accommodates Trp110.       
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Figure 2.15. Apo PD-1 interactions with GDY peptide opens a hydrophobic cavity. Panels (a) and (b) 
illustrate the PD-1 interface cavity volume which is plotted in Figure 2.4b. (a) Snapshot from simulation of 
human PD-1 interacting with the GDG peptide. The PD-1 interface cavity volume is shown in red surface. 
Although Asn66 is in the open state, the cavity is closed by the closed state of I126. (b) Snapshot from 
simulation of human PD-1 interacting with the GDY peptide. The PD-1 interface cavity volume is shown in 
orange surface. The Y anchor side chain positions Ile134 to pull Ile126 out of the pocket via hydrophobic 
interaction, leaving a large open cavity. 
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Figure 2.16. Replicate trajectories from Figure 2.4a,b,c. Top: Rolling averages of distance between 
Trp110_NE1 (from bound PD-L2) and Asn66_ND2 from MDS of apo PD-1 (blue) alone and interacting with 
GGG (maroon) and GDG (red) peptides. Middle: Rolling averages of PD-1 binding cavity volume from 
simulations of apo PD-1 alone (blue) and interacting with GDG (red) and GDY (orange) peptides. Bottom: 
(f) Ile126 Χ1 rotamer angle from MDS of apo PD-1 interacting with GDG (red), GDY (orange), and ADY 
(yellow) peptides. 
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Figure 2.17. Dynamics of PD-1 binding cavity in the presence of different anchor substitutes. Ile126 Χ1 
rotamer angle from MDs of apo PD-1 interacting with GDF (orange), GDK (grey), and GDH (blue) peptides. 
GDF produces a mostly open interface cavity, while GDK and GDH stabilize the closed surface. 
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Figure 2.18. Model of potent Brystol-Myers-Squibb macrocyclic PD-1 inhibitor. Predicted macrocycle 
binding mode is shown brown, with certain side chains omitted for clarity (see Figure 2.19 for full 
macrocycle structure). Key PD-L1 (yellow)  [20] and pembrolizumab (purple and magenta) [40] interface 
residues from their bound cocrystal structures are shown to highlight predicted native-like contacts. Inset: 
the mGDV segment of the macrocycle aligned to PD-L1’s ADY trigger and pembrolizumab’s corresponding 
interface residues. Green and red spheres represent hydrophobic and polar pharmacophores matched by 
both pembrolizumab and the mGDV macrocycle motif.     
 49 
 
 
Figure 2.19. Predicted interactions of Brystol-Myers-Squibb macrocyclic PD-1 inhibitor. Figure shows the 
2D structure of the patented Brystol-Myers-Squibb macrocycle with the mGDV sequence highlighted in 
magenta. Dashed lines indicate the specific interactions between the macrocycle and the PD-1 interface 
(green circles) that are observed in our binding model. Amino-acid components of the macrocycle are 
labeled, and analogous PD-L1 cocrystal [20] residues that participate in the same interactions are 
indicated in parenthesis. Our binding model recapitulates most native-like contacts present in the human 
PD-1 – PD-L1 cocrystal. 
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3.0 PREDICTING PROTEIN TARGETS FOR DRUG-LIKE COMPOUNDS USING TRANSCRIPTOMICS 
 
 
 
 
3.1 INTRODUCTION 
 
 
Most protein research still focuses on roughly 10% of proteins, and this bias has a profound effect on drug 
discovery, as exemplified by the popular kinase target [53-55]. The origin for this relatively limited 
exploration of the human interactome and the resulting lack of novel drugs for emerging ‘genomic-era’ 
targets has been traced back to the availability of small molecular weight probes for only a narrow set of 
familiar protein families [53]. To break this vicious circle, a new approach is needed that goes beyond 
known targets and old scaffolds, and that benefits from the vast amount of information we now have on 
gene expression, protein interactions, their structures and related diseases. 
 
The current target-centric paradigm relies on high-throughput in-vitro screening of large compound 
libraries against a single protein [56]. This approach has been effective for kinases, GPCRs, and proteases, 
but has produced meager yields for new targets such as protein-protein interactions, which require 
chemotypes often not found in historical libraries [57, 58]. Moreover, these in-vitro biochemical screens 
often cannot provide any context regarding drug activity in the cell, multi-target effects, or toxicity [59, 
60]. On the other hand, the goal of leveraging new chemistries would entail a compound-centric approach 
that would test compounds directly on thousands of potential targets. In principle, this is regularly done 
in cell-based phenotypic assays, but it is often unclear how to identify potential molecular targets in these 
experiments [61-63]. Understanding how cells respond when specific interactions are disrupted is not only 
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essential for target identification but also for developing therapies that might restore perturbed disease 
networks to their native states. 
 
Compound-centric computational approaches are now commonly applied to predict drug–target 
interactions by leveraging existing data. However, many of these methods extrapolate from known 
chemistry, structural homology, and/or functionally related compounds, and excel in target prediction 
only when the query compound is chemically or functionally similar to known drugs [64-69]. Other 
structure-based methods such as molecular docking are able to evaluate novel chemistries, but are limited 
by the availability of protein structures [70-72], inadequate scoring functions, and excessive computing 
times, which render structure-based methods ill-suited for genome-wide virtual screening [73].  
 
More recently, a new paradigm for predicting molecular interactions using cellular gene expression 
profiles has emerged [74-76]. Previous work has shown that distinct inhibitors of the same protein target 
produce similar transcriptional responses [77]. Related studies have predicted secondary pathways 
affected by known inhibitors by identifying genes that, when null-mutated, diminish the inhibitory 
expression signature of drug-treated cells [78].  When no target information is available for the compound 
in question or related compounds, alternate approaches have mapped drug-induced differential gene 
expression levels onto known protein interaction network topologies and prioritized potential targets by 
identifying highly perturbed subnetworks [79-81]. These studies predicted roughly 20% of known targets 
within the top 100 ranked genes (see Chapter 3.4 for details), but did not predict or validate any previously 
unknown interactions. 
 
The NIH’s Library of Integrated Cellular Signatures (LINCS) project presents an opportunity to leverage 
gene expression signatures from other types of cellular perturbations for the purpose of drug-target 
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interaction prediction. Specifically, the LINCS L1000 dataset contains cellular mRNA signatures from 
treatments with 20,000+ small molecules and 20,000+ gene over-expression (cDNA) or knockdown (sh-
RNA) experiments. Based on the hypothesis that drugs which inhibit their target(s) should yield similar 
network-level effects to silencing the target gene(s) (Figure 3.1a), we calculated correlations between the 
expression signatures of thousands of small molecule treatments and gene knockdowns in the same cells. 
We used the strength of these correlations to rank potential targets for a validation set of 29 FDA-
approved drugs tested in the seven most abundant LINCS cell lines. We evaluate both direct signature 
correlations between drug treatments and knockdowns of their potential targets, as well as indirect 
signature correlations with knockdowns of proteins up/down-stream of potential targets. We combined 
these correlation features with additional gene annotation, protein interaction and cell-specific features 
in a supervised learning framework and use Random Forest (RF) [82, 83] to predict each drug’s target, 
achieving a top 100 target prediction accuracy of 55%, which we show is due primarily to our novel 
correlation features.  
 
Finally, to filter out false positives and further enrich our predictions, we used molecular docking to 
evaluate the structural compatibility of the RF-predicted compound–target pairs. This orthogonal analysis 
significantly improved our prediction accuracy on an expanded validation set of 152 FDA-approved drugs, 
obtaining top-10 and top-100 accuracies of 26% and 41%, respectively, more than double that of 
aforementioned previous methods. We applied our pipeline to 1680 small molecules profiled in LINCS and 
experimentally validated seven potential first-in-class inhibitors for high-impact cancer targets HRAS, 
KRAS, CHIP, and PDK1. 
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Figure 3.1. Drug and gene knockdown induced mRNA expression profile correlations reveal drug-target 
interactions. (a) Illustration of our main hypothesis: we expect a drug-induced mRNA signature to 
correlate with the knockdown signature of the drug’s target gene and/or genes on the same pathway(s). 
(b,c) mRNA signature from knockdown of proteasome gene PSMA1 does not significantly correlate with 
signature induced by tubulin-binding drug mebendazole, but shows strong correlation with signature from 
proteasome inhibitor bortezomib. Data points represent differential expression levels (Z-scores) the 978 
landmark genes measured in the LINCS L1000 experiments. (d,e) Signature from tubulin-binding drug 
vinblastine shows little signature correlation with knockdown of its target TUBA1A, but instead correlates 
with the knockdown of functionally related genes, such as RUVBL1.       
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These novel inhibitor candidates validated our hypothesis that drug treatments and target knockdowns 
cause similar disruptions of cellular protein networks that produce directly correlating differential 
expression patterns. More interestingly, we discover that these correlations can occur for knockdowns of 
the drug’s actual protein target(s) and/or for genes up/downstream of the target(s). We refer to the latter 
as “indirect correlations”. Several aspects of our approach represent significant step forwards from 
previous work exploring expression correlations as a means of predicting molecular interactions [84, 85]. 
Primarily, we do not assume anything about the small molecule or its likely protein target/pathway and 
our evaluation of both direct and indirect correlations allow us to screen compounds at a much larger 
scale and with higher accuracy than has been done previously. Furthermore, to our knowledge, this is the 
first time that pathway connectivity is explicitly considered by indirect correlational effects between drugs 
and knockdowns of target interaction partners. This approach helps to visualize and quantify the impact 
of drugs at the cell level and significantly improves in the translational potential of gene expression data 
to various realms of chemical biology and medicine. Finally, we open source our predictions and methods, 
providing enriched sets of likely active compounds for hundreds of human targets and presenting a new 
avenue for identifying suitable (multi-) targets for novel chemistries and accelerating the discovery of 
chemical probes of protein function. 
 
 
 
3.2 RESULTS 
 
3.2.1 Preliminary prediction of drug targets using expression profile correlation features.  
 
We constructed a validation set of 29 FDA-approved drugs that had been tested in at least seven LINCS 
cells lines, and whose known targets were among 2634 genes knocked down in the same cell lines. For 
these drugs, we ranked potential targets using the direct correlation between the drug-induced mRNA 
expression signature and the knockdown-induced signatures of potential targets (Figure 3.1b,c). For each 
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cell line, the 2634 knockdown signatures were sorted by their Pearson correlation with the expression 
signature of the drug in that cell line. We used each gene’s lowest rank across all cell lines to produce a 
final ranking of potential targets for the given drug. Using this approach, we predicted known targets in 
the top 100 potential targets for 8/29 validation compounds (Table 3.1). Indirect correlations were 
evaluated by the fraction of a potential target’s known interaction partners (cf. BioGrid [86]) whose 
knockdown signatures correlated strongly with the drug-induced signature. Ranking by indirect 
correlations predicted the known target in the top 100 for 10 of our 29 validation compounds (Table 3.1). 
Interestingly, several of these compounds showed little correlation with the knockdown of their targets 
(Figure 3.1d,e), with only 3/10 targets correctly predicted using the direct correlation feature alone. 
 
It is well known that expression profiles vary between cell types [87]. Thus, we constructed a cell selection 
feature to determine the most “active” cell line, defined as the cell line producing the lowest correlation 
between the drug-induced signature and the control signature. Ranking by direct correlations within the 
most active cell line for each drug predicted six known targets in the top 100 (Table 3.1). However, all six 
of these targets were already predicted by either direct or indirect correlations, strongly suggesting that 
scanning for the optimal correlation across all cell lines is a better strategy than trying to identify the most 
relevant cell type by apparent activity. 
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Table 3.1. Performance of target prediction using different features and methods on the 29 FDA-
approved drugs tested in 7 cell lines. DIR: direct correlation feature; IND: indirect correlation feature; CS: 
cell selection feature; MAX: maximum differential expression feature; MEAN: mean differential 
expression feature; LR: logistic regression; RF: random forest. Values are for the ranking of the top known 
target for each drug.  
Drug Random DIR IND CS MAX MEAN LR RF 
vinorelbine 310 126 128 1318 1690 425 28 88 
dexamethasone 1498 1891 284 943 315 1143 757 157 
dasatinib 2325 1009 94 222 290 2621 182 532 
vincristine 1979 473 439 386 2231 2196 456 37 
mycophenolate-mofetil 564 1100 1263 2986 100 301 3064 3086 
amlodipine 995 1338 2439 1801 1875 974 3037 650 
lovastatin 1712 72 811 2078 1124 1068 1334 55 
clobetasol 2194 820 21 157 74 15 38 65 
calcitriol 2514 1059 2938 221 125 1814 1299 252 
flutamide 919 2604 69 2806 463 298 702 647 
prednisolone 2382 1439 206 787 402 1068 257 23 
nifedipine 940 1225 1465 1285 88 322 3037 2249 
vemurafenib 1042 1 82 1 1149 1403 22 2 
glibenclamide 29 1415 2028 409 1059 740 1300 366 
digoxin 2376 73 1470 118 828 567 732 44 
bortezomib 1882 1 1 2 2546 2513 24 5 
vinblastine 1612 515 56 100 224 377 38 2 
digitoxin 573 89 430 216 521 653 79 50 
losartan 645 489 988 770 636 31 735 1931 
pitavastatin 1855 1976 1036 1117 90 527 1632 373 
digoxin 69 521 776 194 127 559 208 64 
hydrocortisone 303 312 72 58 93 122 29 17 
paclitaxel 2299 74 121 47 371 1862 79 19 
lovastatin 988 1 735 1587 1698 1484 128 100 
irinotecan 1742 1023 20 236 128 1886 46 160 
vincristine 1394 96 74 17 1272 69 28 9 
vinblastine 1359 490 75 1383 373 1735 35 2 
raloxifene 2080 2883 1818 1172 1064 479 1114 2520 
digoxin 1005 102 1066 112 2096 2027 252 167 
Mean Ranking 1365 800.6 724.3 776.9 794.9 1009.6 712.8 471.4 
Top 100 2 8 10 6 5 3 11 16 
    
 57 
Finally, to incorporate the findings of previous studies that suggest that drug treatments often up/down 
regulate the expression of their target’s interaction partners [79-81], we constructed two features to 
report directly on the drug-induced differential expression of potential targets’ interaction partners. 
These features compute the maximum and the mean differential expression levels of potential targets’ 
interaction partners in the drug-induced expression profile. The lowest rank of each potential target 
across all cell lines is used in a final ranking. Though neither expression feature produces top 100 
accuracies better than those of our correlation features, maximum differential expression identifies three 
new targets that were not identified using any of the previous features (Table 3.1). 
 
3.2.2 Combining individual features using random forest (RF).  
 
While each of the features in Table 3.1 performed better than random, combining them further improved 
results. Using Leave-One-Out Cross Validation (LOOCV) for each drug, logistic regression [83] correctly 
identified known targets in the top 100 predictions for 11 out of 29 drugs and improved the average 
known target ranking of all drugs (Table 3.1). However, logistic regression assumes that features are 
independent, which is not the case for our dataset given the complexity and density of cellular protein 
interaction networks. Hence, we used RF, which is able to learn more sophisticated decision boundaries 
[88]. Following the same LOOCV procedure, the RF classifier led to much better results than the baseline 
logistic regression, correctly finding the target in the top 100 for 16 out of 29 drugs (55%) (Table 3.1). 
Without further training, we tested the RF approach on the remaining 123 FDA-approved drugs that had 
been profiled in 4, 5, and 6 different LINCS cell lines, and whose known targets were among 3104 genes 
knocked down in the same cells. We predicted known targets for 32 drugs (26%) in the top 100 (Additional 
File 3.1), an encouraging result given the relatively small size of the training set and the expected decline 
in accuracy as the number of cell lines decreases (Table 3.2). 
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Table 3.2. Performance of two random forest models on validation set of 152 FDA-approved drugs as 
a function of cells tested. The number of drugs with targets ranked in top 100/50 are shown for the “on-
the-fly” and “two-level” RF classification models. Results are divided into subsets of drugs profiled in 
different numbers of cell lines. Note that the success rate for RF is significant with p < 10-6 based on 
randomization tests (Figure 3.8). 
 
# of Cells All 7 6 5 4 
# of Drugs 152 29 30 42 51 
On-the-fly      
Top 100 58 13 15 16 14 
Top 50 42 10 10 12 10 
Top 100% 38% 45% 50% 38% 27% 
Top 50% 28% 34% 33% 29% 20% 
Two-level      
Top 100 63 14 15 22 13 
Top 50 54 12 14 20 8 
Top 100% 41% 48% 50% 52% 25% 
Top 50% 36% 41% 47% 48% 16% 
 
 
Re-training on the full set of 152 drugs and validating using LOOCV, we tested two alternative RF models: 
“on-the-fly”, which learns drug-specific classifiers trained on the set of drugs profiled in the same cell 
types, and “two-level”, which learns a single classifier trained on experiments from all training drugs (see 
Chapter 3.4 for details). The performances of both methods as a function of the number of cell lines 
profiled are summarized in Table 3.2. On-the-fly RF correctly ranked the targets of 58 out of 152 drugs in 
the top 100 (38%), with 42 of them in top 50 (28%). Two-level RF produced better enrichment, correctly 
predicting targets for 63 drugs in the top 100 (41%), and for 54 drugs in the top 50 (36%). In sharp contrast, 
random rankings (based on 20000 permutations) leads to only 7% of drugs with targets in the 100, 
indicating that both our training/testing and LOOCV results are extremely significant (Figure 3.8). It is also 
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noteworthy that the top-100 accuracy of the two-level RF analysis increases to 50% if we only consider 
drugs treated in 5 or more cell lines. 
 
3.2.3 Gene ontology analysis of protein targets.  
 
Next, we analyzed in what context our Random Forest analysis was most successful. To do this, we divided 
the 152 drugs in our training data into “successful” predictions (the 63 drugs for which the correct target 
was ranked in the top 100), and “unsuccessful” predictions. We also divided the known targets into those 
that were correctly predicted and those that were not. We considered several different ways to 
characterize small molecules including molecular weight, solubility, and hydrophobicity, but none of these 
seemed to significantly correlate with our “successful” and “unsuccessful” classifications. Next, we used 
gene ontology to test for enrichment of “successful” and “unsuccessful” targets. Interestingly, we found 
that “successful” targets were significantly associated with intracellular categories, while the 
“unsuccessful” targets were mostly associated with transmembrane and extracellular categories (Table 
3.4). 
 
Based on this result we further incorporated cellular component as a feature in our two-level RF. We 
encode this feature by assigning 1 to the intracellular genes and -1 to the extracellular ones. We ran the 
two-level random forest with this additional feature included and demonstrated that the cellular 
component increases the number of top 100 genes to 66 and top 50 genes to 55. 
 
3.2.4 Structural enrichment of genomic predictions.  
 
Figures 3.1d,e show that the gene regulatory effects of TUBA1A inhibition by the drug vinblastine manifest 
primarily as indirect correlations with knockdowns of the target’s interaction partners, such as RUVBL1, 
rather than via direct correlation with knockdown of the target. Such cases reflect the intrinsic 
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connectivity of cellular signaling networks, which sometimes produce gene expression correlations that 
are ambiguous with respect to which of the interacting proteins in the affected pathway is the drug’s 
actual target. Our pipeline eliminates some of these false positives using an orthogonal structure-based 
docking scheme that, although limited to targets with known structure, allows us to significantly improve 
our prediction accuracy. After performing RF classification on the validation set, we mined the Protein 
Data Bank (PDB) [89] to generated structural models of the potential targets for our 63 “hits” - drugs for 
which we correctly identified the known target in the top 100. We selected one or more representative 
crystal structures for each potential target gene, optimizing for sequence coverage and structural 
resolution (see Chapter 3.4). We then docked hits to their top 100 potential targets and ranked using a 
prospectively validated pipeline [90-93]. 
 
On average, crystal structures were available for 69 out of the top 100 potential targets for each 
compound, and structures of known targets were available for 53 of the 63 hits. In order to avoid 
redocking into cocrystals of our hits, we made sure to exclude from our analysis all crystal structures 
containing these 53 ligands, ensuring that our results would not depend on prior knowledge of 
interaction partners or binding modes. As shown in Figure 3.2, molecular docking scores improved the 
re-ranking of the known target for 40 of the 53 drugs, with a mean and median improvement of 13 and 
9, respectively. Based on genomic data alone, the known target was ranked in the top 10 for 40% of the 
63 hits. After structural re-ranking, 65% had their known targets in the top 10 candidates, and this value 
improved to 75% in the subset of 53 drugs with known target structures. These results demonstrate the 
orthogonality of the genomic and structural screens, showing that molecular docking can efficiently 
screen false positives in our gene expression-based predictions. 
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Figure 3.2. Structural enrichment of genomic target predictions. Predicted ranking (lower is better) of 
the highest-ranking known target for the 53 hits in our validation set with known target structures. 
Percentile rankings are shown following RF analysis (blue), and following structural re-ranking (orange). 
Drug names/IDs are listed in Additional File 3.2. 
 
3.2.5 Identifying new interactions in the LINCS dataset.  
 
After validating our approach on known drug targets, we applied our pipeline to a test set of 1680 small 
molecules and 3333 gene knockdowns and predicted several novel interactions. We applied our pipeline 
(Figure 3.3) in both compound-centric (target prediction) and target-centric (virtual screening) contexts, 
in each case producing a final, enriched subset of roughly 10 predictions (either compounds or targets) 
that we tested experimentally. In compound-centric analyses, we performing molecular docking on the 
available structures of the input compound’s top-100 RF-predicted targets. In target-centric analyses, we 
ran the RF on our full test set, identified compounds for which the input protein is ranked in the top 100 
potential targets, and then docked these candidate inhibitors to the target. In both applications, we 
analyzed the final docking score distributions and applied a 50% cutoff threshold to identify highly 
enriched compound/target hits. Structural analysis further facilitated visual validation of the docking 
models of predicted hits, thereby minimizing false positives. 
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Figure 3.3. Workflow of combined genomic (green) and structural (blue) pipeline for drug-target 
interaction prediction. Approximate numbers of proteins/compounds in each phase are indicated on the 
left. 
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3.2.6 Target-centric prediction of novel RAS inhibitors.  
 
Our first application consisted in identifying novel binders of the high-impact and historically 
“undruggable” RAS-family oncoproteins. HRAS and KRAS are among the most frequently mutated genes 
in human cancers [94, 95]. However, despite the extensive structural data available and tremendous 
efforts to target them with small-molecule therapeutics, as of yet no RAS-targeting drug candidates have 
shown success in clinical trials [96-98].  
 
 
 
Figure 3.4. HRAS/KRAS inhibitors predicted based on direct correlations and docked poses show direct 
binding in SPR assays. Differential gene expression profiles of (a) Phloretin and (b) RS-39604 cell 
treatments and KRAS and HRAS knockdown experiments, respectively. Several functionally related genes 
listed in BioGrid [86] are indicated to demonstrate the relevance of these profiles as suggestive of direct 
drug-target interactions. Models of (c) phloretin and (d) RS-39604 bound to an allosteric site on the KRAS 
and HRAS catalytic domains, respectively. (e) SPR titration response curves for (e) phloretin and (f) RS-
39604 binding to KRAS and HRAS, respectively, compared to DCAI positive control. 
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Among the 1680 compounds in our test set, 84 and 156 were predicted (within the top-100) to target 
KRAS and HRAS, respectively. These compounds produced mRNA perturbation signatures that correlated 
strongly with knockdowns of KRAS (Figure 3.4a), and HRAS (Figure 3.4b). Of note, differential expression 
of genes functionally related to K/HRAS, i.e. FGFR4, FGFR2, FRS1, inform on novel regulatory phenotypes 
responding to both compound inhibition and gene knock out. We docked predicted compounds to our 
representative structures of KRAS (PDB ID: 4DSO [96]) and HRAS (PDB ID: 4G0N [99]) (Figure 3.4c,d). RF 
ranking and docking score distributions were compared to select compounds from our enriched datasets 
that were both commercially available and moderately priced. Docking models of promising candidates 
were also examined visually such that to reject models with unmatched hydrogen bonds [100] and select 
those that showed suitable mechanisms of action (see, e.g., Figure 3.4c,d). We purchased six potential 
HRAS inhibitors and five potential KRAS inhibitors for experimental validation (Table 3.5). 
 
Our SPR assay measured direct binding of predicted inhibitors to AviTagged HRAS and KRAS. Initial 100 
µM screens showed binding response for compounds RS-3906 against HRAS and phloretin against KRAS, 
and subsequent titrations confirmed binding at µM concentrations (Figure 3.4e,f), comparable to the DCAI 
positive control [96]. 
 
3.2.7 Target-centric prediction of novel CHIP inhibitors.  
 
Next, we targeted STUB1, also known as CHIP (the carboxy-terminus of Hsc70 interacting protein), an E3 
ubiquitin ligase that manages the turnover of over 60 cellular substrates [101], which to our knowledge 
lacks specific inhibitors. CHIP interacts with the Hsp70 and Hsp90 molecular chaperones via its TPR motif, 
which recruits protein substrates and catalyzes their ubiquitination. Thus, treatment with small molecules 
that inhibit CHIP may prove valuable for pathologies where substrates are prematurely destroyed by the 
ubiquitin-proteasome system [102].  
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The screening of the 1680 LINCS small molecules profiled in at least four cell lines predicted 104 
compounds with CHIP among the top 100 targets. We docked these molecules to our representative 
structure of the TPR domain of CHIP (PDB ID: 2C2L [103]), for which we had an available fluorescence 
polarization (FP) assay. The RF ranking and docking score distributions were compared to select 
compounds highly enriched in one or both scoring metrics. We next visually examined the docking models 
of top ranking/scoring hits to select those that show suitable mechanisms of action, and purchased six 
compounds for testing (Table 3.6). In parallel, we performed a pharmacophore-based virtual screen of the 
ZINC database [104] using the ZincPharmer [93] server, followed by the same structural optimization [90-
93] performed on the LINCS compounds. We purchased seven of the resulting ZINC compounds for 
parallel testing. 
 
Our FP assay measured competition with a natural peptide substrate for the CHIP TPR domain. We found 
that four (out of six) of our LINCS compounds reliably reduced substrate binding (Figure 3.5a,b), while 
three (out of seven) ZINC compounds did so to a modest degree (Figure 3.9). The two strongest binders 
were LINCS compounds 2.1 and 2.2. A functional assay also verified that 2.1 and 2.2 prevented substrate 
ubiquitination and CHIP autoubiquitination (Figure 3.5c,d, Figure 3.10). Compounds 2.1 and 2.2 also 
prevented ubiquitination of an alternate substrate that was tested subsequently (Figure 3.11). 
Importantly, the predicted binding modes of these two compounds did not match the pharmacophore 
model of the TPR-HSP90 interaction [103], which was used to screen the ZINC database (Figure 3.12). The 
latter emphasizes the power of our approach to identify novel compounds and mechanisms of action to 
targets without known inhibitors. 
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Figure 3.5. Predicted inhibitors show direct binding to and functional inhibition of CHIP. (a,b) Predicted 
CHIP inhibitors disrupt binding to chaperone peptide by fluorescence polarization. High ranked (a) and 
low ranked (b) compounds were tested for the ability to compete with a known TPR ligand (5-FAM-
GSGPTIEEVD, 0.1 µM) for binding to CHIP (0.5 µM). Results are the average and standard error of the 
mean of two experiments each performed in triplicate. (c,d) CHIP inhibitors prevent ubiquitination by 
CHIP in vitro. (c) Quantification of substrate ubiquitination by CHIP from Anti-GST western blot 
experiments with tested compounds at 500µM, blotted as in Figure 3.10a and normalized to DMSO 
treated control (2.1, 2.2: N=4; all other compounds: N=2). (d) Quantification of total ubiquitination by 
CHIP from Anti-GST western blot experiments with tested compounds at 500µM, blotted as in Figure 
3.10b and normalized to ubiquitination by a DMSO treated control (all compounds: N=2). 
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Figure 3.6. mRNA expression signature of CHIP inhibitor 2.1 correlates with knockdown of CHIP 
interacting partners. The figure illustrates the correlation between the mRNA expression profile 
signatures produced by treating cells with 2.1 and by knocking down CHIP interaction partners UbcH5 and 
HSP90. These three perturbations have similar network effects (left), as illustrated by their resulting 
differential expression signatures (right). For clarity, expression signatures show only the subset of LINCS 
landmark genes that are functionally related to CHIP according to BioGRID [86]. 
 
Contrary to the RAS compounds that were identified based on direct correlations between compound 
treatments and RAS knockdowns (Figure 3.4a,b), CHIP hits show almost no direct correlation (𝜌g.h =0.15, 	𝜌g.g = 0.02), but were predicted based on indirect correlations with CHIP interaction partners. 
Figure 3.6 shows the correlating differential gene expression profiles for compound 2.1 and knockdowns 
of the CHIP interaction partners UbcH5 and HSP90, which, along with CHIP, were also predicted as 
potential targets by the RF classifier. However, structural screening ruled out these two partners as 
potential targets because of a lack of favorable binding modes. 
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3.2.8 Compound-centric prediction of a novel target for the drug Wortmannin.  
 
We demonstrated a compound-centric application of our pipeline by analyzing Wortmannin, a selective 
PI3K covalent inhibitor and commonly used cell biological tool. DrugBank [105] lists four known human 
targets of Wortmannin: PIK3CG, PLK1, PIK3R1, and PIK3CA. Of the 100 targets predicted for Wortmannin, 
the PDB contained structures for 75, which we used to re-rank these potential targets. Only one known 
kinase target of Wortmannin, PIK3CA, was detected, and ranked 5th. Our pipeline also ranked 2nd the 
human kinase PDPK1 (PDK1). Although PDK1 is a downstream signaling partner of PI3Ks [106], there is no 
prior evidence of a direct Wortmannin-PDK1 interaction in the literature. Nevertheless, both the strong 
direct correlation of wortmannin with the PDK1 knockdown (Figure 3.7a), and the native-like binding 
mode predicted by our pipeline (Figure 3.7b) suggested a possible interaction. 
 
We experimentally tested this interaction using an alphascreen PDK1 interaction-displacement assay. 
Since we predicted that Wortmannin binds to the PH domain of PDK1 (Figure 3.7b), we measured the 
effect of increasing Wortmannin concentrations on the interaction of PDK1 with the second messenger 
PIP3. We found that Wortmannin specifically increased PDK1-PIP3 interaction, relative to control (Figure 
3.7c). Given that PIP3-mediated recruitment of PDK1 to the membrane is thought to play an important 
regulatory role in the activity of the enzyme [107, 108], a disruptive increase in PDK1-PIP3 interaction 
following treatment with Wortmannin supports our prediction. 
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Figure 3.7. Wortmannin promotes PDK1 – PIP3 binding in vitro. (a) Wortmannin treatment and PDK1 
knockdown experiments produce directly correlating differential gene expression profiles. Several 
functionally related genes listed in BioGrid [86] are indicated to demonstrate the relevance of these 
profiles as suggestive of direct drug-target interactions. (b) Model of wortmannin bound to the PH domain 
of PDK1, compared to known ligand 4PT (PDB ID: 1W1G [109]). (c) Alphascreen PDK1-PIP3 interaction-
displacement assay results for increasing concentrations of wortmannin. Error bars represent the 
standard error on the mean from two parallel runs. (d) Effect of wortmannin on the in-vitro 
phosphorylation of the substrate T308tide by the isolated catalytic domain of PDK1. The two lines are 
from two replicates of the activity assay, with error bars representing the standard error on the mean 
from two parallel runs for each replicate. 
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3.2.9 Comparison to existing target prediction methods.  
 
For completeness, we compared results for our 63 hits from the validation set to those produced by 
available structure and ligand-based methods. HTDocking (HTD) [110] is a structure-based target 
prediction method that docks and scores the input compound against a manually curated set of 607 
human protein structures. For comparison, in our analysis we were able to extract high-quality domain 
structures for 1245 (40%) of the 3104 potential gene targets. PharmMapper (PHM) [111] is a ligand-based 
approach that screens the input compound against pharmacophore models generated from publicly 
available bound drug-target cocrystal structures of 459 human proteins, and then ranks potential targets 
by the degree to which the input compound matches the binding mode of the cocrystalized ligands. The 
scope of HTD is limited by the availability of the target structure, while PHM is limited by chemical and 
structural similarity of active ligands.  
 
HTD and PHM rankings for known targets are shown in Table 3.3, and complete results are shown in 
Additional File 3.3. Our combined genomics-structure method outperforms the structure-based HTD 
server (average ranking of the known target is 13 for our method vs. 50 for the HTD server). This suggests 
that limiting the structural screening to our genomic hits allowed us to predict targets with higher accuracy 
than docking alone. Results when using the PHM server are on average similar to ours. However, PHM 
relies on the availability of ligand-bound crystal structures, which in practice makes this class of methods 
more suitable for drug repurposing than assessing new chemistries or targets. 
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Table 3.3. Comparison of our pipeline to existing drug-target prediction methods. The average ranking 
of the highest ranked known target is listed for all 63 validation ‘hits’, for the subset of 53 validation hits 
with known target structures, and for our seven predicted interactions. ‘Structures available’ indicates the 
average number of top-100 potential targets with available crystal structures for the compound set. 
Rankings are compared between the initial random-forest genomic ranking, the structural re-ranking of 
the top 100 RF predicted targets, the HTDocking server (HTD), and the PharmMapper server (PHM). 
  
Structures 
available 
Genomic 
Rank  
Structural 
Re-rank  
HTD PHM 
All hits  
(n=63) 
69   22 24 56 23 
Hits w/ known target structures 
(n=53) 
71   23 13 50 12 
New predictions 
(n=7) 
73 28 31 n/a n/a 
 
 
With regards to new validated interactions, alternative approaches failed to predict the interactions with 
HRAS, KRAS, and CHIP that were verified by our assays. However, a Wortmannin-PDK1 interaction was 
predicted at the catalytic site by HTD, ranked 540th, and by PHM, ranked 56th. Although we cannot rule 
out a possible kinase domain interaction, a catalytic activity assay showed that Wortmannin had no 
measurable effect on the in vitro phosphorylation of the substrate T308tide by the isolated catalytic 
domain of PDK1 (Figure 3.7d). 
 
 
 
3.3 DISCUSSION 
 
Delineating the role of small molecules in perturbing cellular interaction networks in normal and disease 
states is an important step towards identifying new therapeutic targets and chemistries for drug 
development. To advance on this goal, we developed a novel target prediction method based on the 
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hypothesis that drugs that inhibit a given protein should have similar network-level effects to silencing 
the inhibited gene and/or its up/downstream partners. Using gene expression profiles from knockdown 
and drug treatment experiments in multiple cell types from the LINCS L1000 dataset, we developed 
several correlation-based features and combined them in a random forest (RF) model to predict drug-
target interactions.  
 
On a validation set of 152 FDA-approved drugs we achieve top-100 target prediction accuracy more than 
double that of previous approaches that use differential expression alone [80, 81]. Consistent with our 
underlying hypothesis, the RF results highlight the importance of both direct expression signature 
correlations between drug treatment and knockdown of the gene target (Figure 3.1c, Figure 3.4a,b, Figure 
3.7a) and indirect correlations between the drug and the target’s interacting partners (Figure 3.1e, Figure 
3.6). Contrary to earlier work [79-81], our method is capable of predicting potential targets for any 
compound, even those unrelated to known drugs, and our predictions are open source and available for 
immediate download and testing (http://sb.cs.cmu.edu/Target2/). These include potential targets for 
1680 LINCS small molecules from among 3000+ different human proteins. 
 
Unlike most available ligand-based prediction methods [64-69], the accuracy of our approach does not 
rely on chemical similarity between compounds in the training/test sets. For instance, our screen against 
CHIP, a target with no known small molecule inhibitors, delivered four out of six binding compounds, 
whereas a parallel analysis using a state-of-the-art structure-based virtual screening [90, 112] yielded only 
two weak-binding compounds. Moreover, the predicted mechanisms of actions of the more potent LINCS 
compounds suggest novel interactions that were not prioritized by the ligand-based screen (Figure 3.12).  
 
In contrast to other machine learning methods, our approach reveals important, human-interpretable 
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insights into perturbation-response properties of cellular networks. Direct and indirect gene expression 
profile correlations inform on global regulatory responses triggered by small molecule cell treatments 
(see, e.g., Figures 3.4, 3.6, 3.7). Namely, our genomic screening not only identifies compounds targeting a 
given protein, but also highlight related genes that are affected by the chemical modulation of the target. 
This knowledge is bound to play an important role in the design of polypharmacological therapies. 
 
The experimental validation of our predictions for HRAS, KRAS, CHIP and Wortmannin demonstrate the 
power of our combined genomic and structural pipeline in identifying novel targets and chemotypes. Our 
prospectively identified modulators are the first of their kind – in that they represent the results of a 
virtual target-screening process, rather than traditional high-throughput small molecule screening 
approaches. 
 
Detailed analyses of our predictions suggest several avenues to improve enrichment. We established a 
clear correlation between the number of cell-types screened and the target prediction accuracy. We 
identified that a significant source of false positives are indirect correlations that while important to detect 
the true target, also tend to predict interacting partners as potential targets. Incorporating compound- or 
target-specific features are also likely to improve our results. For instance, we noticed that our prediction 
results were less accurate for membrane proteins, and incorporating a cellular localization feature into 
our RF model increased the number of top-100 hits in our validation set from 63 to 66. 
 
In sum, our method represents a novel application of gene expression data for small molecule–protein 
interaction prediction, with structural analysis further enriching hits to an unprecedented level in our 
proteome-scale screens. The success of our proof-of-concept experiments opens the door for a 
compound-centric drug discovery pipeline that can leverage the relatively small fraction of potentially 
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bioactive compounds that could be of interest for further investigation to become drugs [113]. Compared 
to alternative approaches, our method would be particularly suitable for scanning for targets of newly 
synthesized scaffolds. We are hopeful that our open source method and predictions might be useful to 
other labs around the world for identifying new drugs for key proteins involved in various diseases and 
for better understanding the impact of drug modulation of gene expression. Moreover, our approach 
represents a new framework for extracting robust correlations from intrinsically noisy gene expression 
data that reflect the underlying connectivity of the cellular interactome. 
 
 
3.4 METHODS 
 
3.4.1 Data sources 
 
LINCS: LINCS is an NIH program that generates and curates gene expression profiles across multiple cell 
lines and perturbation types at a massive scale. To date, LINCS has generated millions of gene expression 
profiles (over 150 gigabytes of data) containing small-molecules and genetic gain- (cDNA) and loss-of-
function (sh-RNA) constructs across multiple cell types. Specifically, the LINCS dataset contains 
experiments profiling the effects of 20,143 small-molecule compounds (including known drugs) and 
22,119 genetic constructs for over-expressing or knocking-down genes performed in 18 different cell 
types selected from diverse lineages which span established cancer cell lines, immortalized (but not 
transformed) primary cells, and both cycling and quiescent cells. 
 
The gene expression profiles were measured using a bead-based assay termed the L1000 assay1. To 
increase throughput and save costs, this assay only profiles a set of 978 so-called “landmark genes” and 
                                                        
1 http://support.lincscloud.org/hc/en-us/sections/200437157-L1000-Assay 
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the expression values of other genes can be computationally imputed from this set. Note however, that 
in our analysis we do not rely on such imputation and our methods only need to use the values for the 
measured genes. In our analysis we used level-4 signature values (containing z-scores for each gene in 
each experiment based on repeats relative to population control). Data processing of LINCS was done 
using the l1ktool.2 
 
ChEMBL: To obtain a list of known targets for the drugs in our validation set we used ChEMBL, an open 
large-scale bioactivity database [114]. We retrieved the records of all FDA-approved drugs using the 
ChEMBL web service API3. These records contain the designed targets for the drugs along with their 
synonyms (alternate names) and unique chemical IDs. We used this information to cross-reference these 
drugs with those in LINCS. 
 
Protein-protein interaction and gene ontology: We obtained PPI information for our feature sets from 
BioGRID [86] and HPRD [115], both of which contain curated sets of physical and genetic interactions. We 
retrieved all the records corresponding to protein-protein interactions (PPI) from these data sources and 
converted them to an adjacency list representation. We obtained the cellular localization of proteins from 
the Gene Ontology database [116]. We relied on prior analysis [117] to assign the location of for each 
protein as either “intracellular” (inside of cell) or “extracellular” (outside of cell).  
 
3.4.2 Extracting experiments from LINCS 
 
After determining the subsets of small molecules and cell lines, we obtained the associated experiment 
identifiers known as “distil IDs” from LINCS meta- information. We included only the reproducible distil 
                                                        
2 http://code.lincscloud.org/ 
3 https://www.ebi.ac.uk/chembl/ 
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IDs known as “Gold” IDs. We then extracted the corresponding signature values from LINCS using the 
L1000 Analysis Tools (l1ktools)4. We only extracted the signature values of the 978 “landmark" genes 
because their expression was directly measured, whereas the values of other genes were imputed from 
the data of these landmark genes. 
 
Drug response experiments  
There exist multiple experiments (distil IDs) corresponding to a combination of drug d and cell line c 
(applying drug d to cell line c). Denote the Ndc as the number of experiments for the combination d,c. We 
extracted a matrix of signature values of size 978 × Ndc (number of landmark genes × number of 
experiments) per combination. We next took the median of signature values across different experiments, 
and obtained a 987 × 1 signature vector per combination. The overall drug-response data Δ, therefore, is 
implemented as a MATLAB structure with D = 152 entries, each containing the following fields. 
 
 name:  𝑃𝑒𝑟𝑡𝐼𝐷p  (string) 
 cells:  𝐶𝑒𝑙𝑙𝑠)r (|𝐶p| × 1 string array) 
 signature:  ∆p∙∙ (978 × |𝐶p|) 
 
where 𝑃𝑒𝑟𝑡𝐼𝐷p is the unique internal identifier of a small molecule d in LINCS. ∆p∙∙ contains the expression 
values of drug d across Cd different cell lines. The 𝐶𝑒𝑙𝑙𝑠)r field contains cell line names corresponding to 
the column of ∆p∙∙. 
 
Gene knockdown experiments  
We follow a similar protocol to extract the signature values of gene knockdown experiments. Denote Ngc 
as the number of experiments for the combination of gene g and cell line c (knocking down gene g in cell 
line c). Then, for each combination of g and c we extracted signature values of size 978 × Ngc. After taking 
                                                        
4 https://github.com/cmap/l1ktools 
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the medians across different experiments, we obtain a 978 × 1 vector per combination. The overall gene 
knockdown data Γ has C = 7 entries and each entry contains the following fields: 
 
 name:  𝐶𝑒𝑙𝑙𝑠u (string) 
 genes:  𝑆𝑦𝑚𝑏𝑜𝑙𝑠J{  (|𝐺u| × 1 string array) 
 signature:   Γu∙∙ (978 × |𝐺u|) 
 
where 𝐶𝑒𝑙𝑙𝑠u is the name of the cell line indexed by c.  Γu∙∙ contains the signature values of the knockdown 
of genes in cell line c. The 𝑆𝑦𝑚𝑏𝑜𝑙𝑠J{ field is a subset of gene symbols corresponding to the column 
identifiers of Γu∙∙ under the HGNC naming scheme. 
 
Control experiments 
We also extracted the signatures of control experiments. The signature values for each cell line were 
extracted and we obtained a 978 × 1 vector after taking the medians. We denote the overall control 
experiment data as Ψ. Ψ is of size 978 ×	C and implemented with the following format: 
 
 name:  𝐶𝑒𝑙𝑙𝑠u (string) 
 control: Ψ∙u  (978 × 1) 
 
where Ψ∙u  is the signature column vector for a cell line c. 
 
3.4.3 Building a validation dataset from LINCS 
 
We used ChEMBL to retrieve the reported targets and other meta-information of all FDA-approved drugs, 
and then cross referenced these drugs with the small molecules profiled in LINCS using their primary 
product names, synonyms, canonical SMILES strings and standard InChIKey. Based on this analysis we 
identified 1031 out of approximately 1300 FDA-approved drugs reported in LINCS. However, most of these 
drugs were profiled in only one or very few cell lines, which meant that relatively little response data was 
available for them. We thus further reduced this set to 152 drugs profiled in at least 4 cell lines (Table 3.2) 
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and used these drugs and their known targets as the positive training set. Table 3.9 lists the number of 
drugs and knockdown experiments available for the seven most abundant cell lines in terms of known 
targets profiled that we used in our analysis. 
 
3.4.4 Extracting and integrating features from different data sources 
 
The notation and symbols that we use in constructing and using the genomic features are described in 
Table 3.7 and Table 3.8. Feature construction is summarized below. 
 
Direct correlation: The first feature 𝑓u' ,computes the correlation between the expression profiles 
resulting from a gene knockdown and treatment with the small molecule. The correlation feature, 
denoted as fcor, is constructed as follows: 
 
- For each drug d in Δ (∆p∙∙): 
 
- Denote Td as the intersection of gene symbol indices for cells in Cd: 
  𝑇p =  𝐺uu)r  
 
- Obtain the knockdown signature values of Td  from Γ. Denote this data matrix as Γ)r∙r , which is of 
size |𝐶p| × 978 × |𝑇p|, where for each cell line in Cd  there is a signature matrix of size 978 × |𝑇p|. 
 
- Compute the Pearson's correlation between ∆p∙∙ (978 × |𝐶p|) and Γ)r∙r  (|𝐶p| × 978 × |𝑇p|). 
Specifically, for each cell line 𝑐 ∈ 𝐶p, we compute the correlation between ∆p∙u  and Γu∙r , and obtain 
a correlation vector of size |𝑇p|. This is the correlation between the responses of the cells to the drug 
treatment and their response to the gene knockdown. Each entry in this vector is the correlation of 
978 landmark genes of the drug d in one cell line (∆p∙u) and a knockdown of gene g in the same cell 
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line (Γu∙). In other words, if we collect these correlation vectors for all cell lines in Cd and denote the 
overall correlation feature as fcor: 
 𝑓u'(𝑑, 𝑔, 𝑐) = 𝑐𝑜𝑟𝑟(∆p∙u, Γu∙)     ∀𝑔 ∈ 𝑇p 
 
 
The correlation feature for one drug d, 𝑓u'(𝑑,∙,∙), has a dimension of |𝑇p| × |𝐶p|. 
 
 
Indirect correlation: Information about protein interaction networks may be informative about additional 
knockdown experiments that we might expect to be correlated with the small molecule treatment profile. 
To construct a feature that can utilize this idea we did the following: for each molecule, protein, and cell 
line we computed 𝑓)(𝑑, 𝑔, 𝑐), which encodes the fraction of the known binding partners of g (i.e. the 
proteins interacting with g) in the top X knockdown experiments correlated with this molecule/cell 
compared to what is expected based on the degree of that protein (the number of interaction partners - 
this corrects for hub proteins). We used X = 100 here, though 50 and 200 gave similar results. 
 
The indirect correlation score is constructed as follows: 
 
- For each drug d in Δ (∆p∙∙): 
 
- Obtain Td, as defined above. 
 
- For each cell line c in Cd: 
 
- Sort Td in descending order using the correlation values 𝑓u'(𝑑,∙, 𝑐) 
 
- Denote the sorted gene symbol indices for cell line c as 𝜎u(𝑇p) 
 
- For each knockdown gene g in Td: 
 
- Obtain the set of neighbor gene symbol indices from the PPI adjacency list, denote it as Ng. 
 
- Compute fPC as: 
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𝑓)(𝑑, 𝑔, 𝑐) = 𝑁 ∩ 𝜎u(𝑇p)h:h𝑁 ∩ 𝜎u(𝑇p) + 50 
 𝑓)(𝑑, 𝑔, 𝑐) has the same dimension as 𝑓u'  (|𝑇p| × |𝐶p|). It reflects the fraction of gene g's binding 
partners that are more correlated with drug d in the context of cell line c. We use 50 as the pseudo-count 
to penalize hub proteins, which have substantially more neighbors than others. 
 
Cell selection: While the correlation feature is computed for all cells, it is likely that most drugs are only 
active in certain cell types and not others. Since the ability to consider the cellular context is one of the 
major advantages of our method we added a feature to denote the impact a drug has on a cell line. For 
each drug/molecule d we compute a cell specific feature, 𝑓)(𝑑,∙), which measures the correlation 
between the response expression profile and the control (WT) experiments for that cell. We expect a 
smaller correlation if the drug/molecule is active in this cell, and a larger correlation if it is not. The cell 
selection feature is calculated 
 
Differential expression: In addition to determining the correlation-based rankings of interacting proteins, 
we also took their drug-induced differential expression into account. We constructed two features that 
summarize this information for each protein. These features either encode the average or the max 
(absolute value) expression level of the interaction partners of the potential target protein. 
 
We compute two types of PPI expression scores, denoted as 𝑓(Y  and 𝑓(Y , as follows: 
 
- For each drug d in Δ (∆p∙∙): 
 
- For each knockdown gene g in Td: 
 
- Obtain Ng, as above (the list of neighbors, or interaction partners, of g) 
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- For each cell line c in Cd: 
 
- Find the set of signature values for the neighbors of g, ∆p,e,u  (size 𝑁 × 1) 
 
- Compute the two PPI expression scores as: 
 𝑓(Y(𝑑, 𝑔, 𝑐) = max	(∆p,e,u) 
 𝑓(Y(𝑑, 𝑔, 𝑐) = avg	(∆p,e,u) 
 
 
Feature data structure 
We combined the features for all drugs in a MATLAB structure Ω. Ω has D entries, and each entry Ω(d) has 
the following fields: 
 
 name:  𝑃𝑒𝑟𝑡𝐼𝐷p  (string) 
 targets: 𝑃p (protein targets for d) 
 cells:  𝐶𝑒𝑙𝑙𝑠)r (|𝐶p| × 1 string array) 
 genes: 𝑇p  (common genes across Gc) 
 correlation: 𝑓u'(𝑑,∙,∙) (|𝑇p| × |𝐶p|) 
 PPI correlation: 𝑓)(𝑑,∙,∙) (|𝑇p| × |𝐶p|) 
 max PPI expression: 𝑓(Y(𝑑,∙,∙) (|𝑇p| × |𝐶p|) 
 avg  PPI expression: 𝑓(Y(𝑑,∙,∙) (|𝑇p| × |𝐶p|) 
 cell selection: 𝑓)(𝑑,∙) (|𝐶p| × 1) 
 
There are a total of D = 152 drugs in Ω, and the number of drugs with different values of |𝐶p| are 
summarized in Table 3.2. 
 
3.4.5  Subcellular localization assignment 
 
We obtained the cellular localization of genes from the Gene Ontology Consortium. The GO database 
provides web services to query genes in terms of their associated biological processes, cellular 
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components and molecular functions in a species-independent manner5. We further assign the locations 
as either “intracellular” (inside of cell) or “extracellular” (outside of cell). The detailed assignments are 
shown in Table 3.4. 
 
3.4.6  Classification procedure 
 
Criterion of successful classification 
Due to the intrinsic noise from the data, we define a successful classification for a drug if any of its correct 
targets is enriched into the top K ranked genes, where K can be either 50 or 100. 
 
Analysis of feature importance 
The evaluation of single features was performed using the drugs that have been applied on all seven cell 
lines. There are 29 of these drugs from Ω. We sort (descendingly) the common genes Td for a drug d and 
cell line c using an individual feature 𝑓(𝑑,∙, 𝑐), where 𝑓 is either 𝑓u'  or 𝑓) . Denote 𝜎p(𝑔, 𝑐) as the ranking 
of a gene 𝑔 ∈ 𝑇p in the context of cell line c. Then, we define the overall ranking of a gene, 𝜎p(𝑔), to be 
the best ranking across all seven cell lines: 𝜎p(𝑔) = min	(𝜎p(𝑔, 𝑐)) for 𝑐 ∈ 𝐶p . 
  
Constructing training dataset 
Next, we wish to learn and evaluate classifiers that predict drug targets using all features from the feature 
dataset Ω. We first construct a training data set (design matrix X and its associated labels y) from the 
feature dataset Ω. 
 
For each drug d in Ω, we select the rows corresponding to the targets in Pd from the other feature matrices 
and concatenate them into a row vector. The same cell selection vector is appended to every row of 
                                                        
5 http://geneontology.org/page/go-enrichment-analysis 
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targets. These rows are assigned with a positive label 1. We then randomly sampled 100 non-target genes 
(denoted as 𝜈p) and construct the row vectors the same way as the target genes, and these rows are 
assigned with a negative label 0. In other words, the training matrix and label vector constructed from a 
drug d are of the following format: 
 
𝑋p =
⎣⎢⎢
⎢⎢⎢
⎢⎢⎢
⎢⎢⎡
𝑓u'(𝑑, 𝑃ph,∙) 𝑓)(𝑑, 𝑃ph,∙) 𝑓(Y(𝑑, 𝑃ph,∙) 𝑓(Y(𝑑, 𝑃ph,∙) 𝑓)(𝑑,∙)𝑓u'(𝑑, 𝑃pg,∙) 𝑓)(𝑑, 𝑃pg,∙) 𝑓(Y(𝑑, 𝑃pg,∙) 𝑓(Y(𝑑, 𝑃pg,∙) 𝑓)(𝑑,∙)⋮ ⋮ ⋮ ⋮ ⋮𝑓u'(𝑑, 𝑃pL,∙) 𝑓)(𝑑, 𝑃pL,∙) 𝑓(Y(𝑑, 𝑃pL,∙) 𝑓(Y(𝑑, 𝑃pL,∙) 𝑓)(𝑑,∙)𝑓u'(𝑑, 𝜈ph,∙) 𝑓)(𝑑, 𝜈ph,∙) 𝑓(Y(𝑑, 𝜈ph,∙) 𝑓(Y(𝑑, 𝜈ph,∙) 𝑓)(𝑑,∙)𝑓u'(𝑑, 𝜈pg,∙) 𝑓)(𝑑, 𝜈pg,∙) 𝑓(Y(𝑑, 𝜈pg,∙) 𝑓(Y(𝑑, 𝜈pg,∙) 𝑓)(𝑑,∙)⋮ ⋮ ⋮ ⋮ ⋮𝑓u'(𝑑, 𝜈ph,∙) 𝑓)(𝑑, 𝜈ph,∙) 𝑓(Y(𝑑, 𝜈ph,∙) 𝑓(Y(𝑑, 𝜈ph,∙) 𝑓)(𝑑,∙)⎦⎥⎥
⎥⎥⎥
⎥⎥⎥
⎥⎥⎤
; 𝑦p =
⎣⎢⎢
⎢⎢⎢
⎢⎢⎢
⎢⎢⎡
11⋮100⋮0⎦⎥⎥
⎥⎥⎥
⎥⎥⎥
⎥⎥⎤
 
 
where 𝑚 = |𝑃p|, the total number of targets for drug d. Therefore, the training matrix Xd for drug d is of 
size (𝑚 + 100) × 	5|𝐶p|, and label vector 𝑦p has length (𝑚 + 100). 
 
3.4.7 Extending random forests to drugs with missing features 
 
Since our goal here is to predict targets for as many small molecules as possible, we did not want to restrict 
our analysis to molecules that were only profiled in a large number of cell lines. As noted above, requiring 
at least seven cell lines reduces the number of known drugs that can be evaluated from 152 to 29 and 
leads to a similar reduction in the number of novel small molecules that can be evaluated. Thus, it is highly 
desirable that our classifiers can handle missing data (i.e., cells for which experiments were not 
performed). To this end, we developed two distinct methods to deal with different compound-specific cell 
line combinations and extended the random forest [82, 83] model so that can handle molecules profiled 
in less than seven (but more than four) cell types.  
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In the first method we simply build the random forest “on-the-fly”. For a given drug i, we iterate through 
all other drugs in Ω and test if a drug d was profiled in at least all cells which drug i was profiled in. In other 
words, we test if 𝐶§ ⊆ 𝐶p  and if so we extract the features of corresponding cell lines in Ci from Ω(p) and 
include them in the training data. After we include data for all compatible drugs we can use the training 
data to train and apply a random forest for the given drug i. We note that for any drug in Ω, there are at 
least 28 compatible drugs because 29 drugs have been applied to all seven cell lines. However, the main 
disadvantage of this method is that we need to train separate random forest for every test drug. 
 
In the second method we perform a “two-level” random forest construction process. Here, in addition to 
the standard step of selecting a (random) subset of the features for each of the trees in the forest we 
included a step that selected a (random) subset of cells for each of the trees. Specifically, in the first step, 
we randomly sample four cell lines from the seven total cell lines (denoted as Ci). In the second step, we 
find all drugs 𝑑 ∈ Ω such that 𝐶§ ⊆ 𝐶p , extract their features, and use them to train that tree. We repeat 
this process 3500 times, such that each combination of four cell lines is expected to have roughly 100 
trees (©74« = 35). To apply this two-level random forest to a test drug t with cell line profile Ct, we select 
from the forest those decision trees i for which 𝐶§ ⊆ 𝐶¬  and use them to predict the targets for t. Note 
that unlike the on-the-fly method above, here we only need to train one forest for the entire prediction 
task. 
 
3.4.8 Generating structural models for docking 
 
In order to use molecular docking to enrich of our random forest predictions, we needed to generate 
structural models for the genes profiled in LINCS. The union of our top 100 target predictions for the 1680 
small molecules profiled in LINCS in at least four cell lines consisted of 3333 unique human genes. We 
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used a python script (available on github6) to mine the PDB for structures of these genes via its RESTful 
Web Service interface7 using Uniprot primary gene name as the search criteria. Crystal structures were 
available for 1245 of the 3333 human genes in our analysis. The mean and median numbers of structures 
for these 1245 genes were 11 and 3, respectively. We then analyzed the structures for each gene and 
selected representative structures that would be used for docking. Representative structure selection was 
performed automatically using a procedure (explained below) that attempts to optimize sequence 
coverage, structural resolution, and structural diversity. 
 
To select representative structures, we first divided each gene’s structures into “high” and “low” 
resolution categories using a 2.0 Å threshold. Small structures with less than 20 amino acids were 
discarded. We then used a greedy algorithm to assess sequence coverage for the remaining structures 
and select (as representative) the fewest and highest resolution structures that would cover the most of 
the protein sequence. Redundant structures, defined as structures that did not contain at least 10 residues 
that were not contained in any of the larger or higher resolution structures, were discarded unless they 
represented a unique conformation of the protein. Protein conformation was evaluated using ProDy [118] 
and was considered “unique” if the redundant structure had an all atom RMSD to each of the other 
representative structures that was above a cutoff threshold that could range between 4.0 Å and 10.0 Å. 
The specific value of the threshold used for each gene was chosen to try to minimize the number of 
redundant structures that would be docked against, and higher cutoffs were used for genes that had many 
redundant structures representing different conformations. After selection, the mean and median 
numbers of representative structures per gene were 2 and 1, respectively. Each representative structure 
consisted of exactly one amino acid chain and coordinated ions but without cocrystal ligands or 
                                                        
6 https://github.com/npabon/generate_gene_models 
7 https://www.rcsb.org/pdb/software/rest.do 
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crystallographic waters. We note that this automated procedure is not necessarily tailored to produce 
representative structures for functional oligomers, since only one chain is considered at a time.  
 
3.4.9 Docking procedure 
 
Compounds were docked to representative structures of their predicted targets with smina [91], using 
default exhaustiveness and a 6 Å buffer to define the box around each potential binding site. Docked 
poses across predicted binding sites [119] on a given target were compared and the highest scoring pose 
of each compound was selected for further analyses [90-93] and comparison to other targets/compounds.   
 
3.4.10 Comparison to previous expression perturbation target prediction methods 
 
Unlike our method which uses both drug-induced and knockdown-induced mRNA expression 
perturbations, previous target prediction methods analyzed only the drug data within the context of 
protein interaction networks [80, 81]. As their primary measurement of prediction accuracy, these works 
generally report the aggregate Area Under the Curve (AUC) of their gene rankings across all validation 
compounds. The studies mentioned above achieve AUC values of 0.9 and higher in ranking between 
11,000 and 18,000 potential gene targets for each compound. To compare these results against our 
method, we examined the reported AUC curves and calculated the percentage of compounds for which 
the correct target was ranked within the top 100 potential targets. Both studies achieved top-100 accuracy 
of 20-21%. 
 
3.4.11 Experimental Assays involving HRAS and KRAS 
 
Surface Plasmon Resonance Spectroscopy: SPR binding experiments were performed on a Biacore S200 
instrument (GE, Piscatawy, NJ).  Neutravidin (Pierce) was coupled to the carboxymethylated dextran 
surface of a CM5 sensor chip (GE, Piscatawy, NJ) using standard amine coupling chemistry to capture 
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approximately 10,000 RU.  Avi-tagged HRAS and KRAS GDP were captured on flows 2, 3 4 with densities 
of 2450, 2550 and 2960 RU respectively. A titration series of compounds 6, 7, and 12 diluted from 200 – 
0.78 µM (seven 2-fold serial dilutions) and compound 15 diluted from 100 – 1.56 µM (six 2-fold serial 
dilutions) were prepared in 20mM Hepes, 150mM NaCl, 5mM MgCl2, 1mM TCEP, 0.01% Tween 20, 5% 
DMSO, 5µM GDP, pH 7.4. A positive control for KRAS-GDP of 250 µM DCAI was included. All compounds 
were injected over all flow cells at 30 µl/min. The data was processed by subtracting binding responses 
on the reference flow cells, buffer injections and in addition samples were also corrected for DMSO 
mismatches using a DMSO standard curve. 
 
Protein production: Avi-HRAS(1-189) and Avi-KRAS4b(2-188) were expressed in E. coli as His6-MBP-tev-
Avi-HRAS(1-189) and His6-MBP-tev- Avi-KRAS4b(2-188), respectively, and purified essentially as 
previously described [120] for a His6-MBP-tev-fusion protein. 
 
3.4.12 Experimental assays involving CHIP 
 
Materials: Rabbit anti-GST polyclonal antibody conjugated to HRP was purchased from Abcam (ab3416), 
mouse anti-ubiquitin monoclonal antibody was purchased from Santa Cruz Biotechnology (sc-8017), and 
horse anti-mouse polyclonal antibody conjugated to HRP was purchased from Cell Signaling Technology 
(7076S). E2 enzyme UbcH5b and recombinant human ubiquitin were obtained from Boston Biochem (E2-
662 and U-100H, respectively). 
 
Protein purifications: His-Ube1, His-CHIP, GST-Hsc70395-646, and GST-AT-3 JD were expressed in and 
purified from E. coli BL21(DE3) competent cells (New England Biolabs). Ube1/PET21d was a gift from Dr. 
Cynthia Wolberger (Addgene plasmid #34965) [121], pET151/D-TOPO CHIP and pGST‖2 Hsc70395-646 were 
gifts from Dr. Saurav Misra [122, 123], and pGEX6p1 AT-3 JD was a gift from Dr. Matthew Scaglione [124, 
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125]. Transformed cultures were incubated in Luria broth with 100 µg/mL ampicillin at 37°C and shaken 
at 225 rpm until an OD600 of 0.3 was attained.  Protein expression was then induced with 500µM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and cultures were incubated for 24 hrs. at 18°C (15°C for cells 
expressing GST-Hsc70395-646 or GST-AT-3 JD) before the cells were harvested at 5000 rpm for 10 min at 4°C 
using an F7S-4x1000y rotor for the Sorvall RC-5B Plus Superspeed centrifuge. Cell pellets were stored at -
80°C.  
 
Cells harboring His-Ube1 or His-CHIP were thawed and lysed by incubation in lysis buffer (10 mM 
imidazole, 50 mM NaPO4 pH 8, 300 mM NaCl, 5 mM 2-mercaptoethanol, 0.25% Triton-100X, 2 mg/mL 
lysozyme) for 30 min on ice followed by sonication. Purification of Ube1 required addition of protease 
inhibitors (1% PMSF, 0.2% leupeptin, 0.1% pepstatin A) during lysis and throughout purification. After 
centrifugation, lysates were applied to Ni-NTA agarose resin (Qiagen), the column was washed with 30 
mM imidazole, and proteins were eluted with 200 mM imidazole. Peak fractions containing His-Ube1 were 
pooled, dialyzed into 20 mM HEPES pH 7.4, 20 mM NaCl, and further purified by anion exchange 
chromatography over DEAE-Sepharose (GE Healthcare). Bound protein was eluted with a 50-300 mM NaCl 
gradient. Purified His-Ube1 and His-CHIP were dialyzed into 50 mM HEPES pH 7, 50 mM NaCl, and His-
CHIP was further concentrated by centrifugal filtration (Millipore). 
 
Cells harboring GST-Hsc70395-646 or GST-AT-3 JD were similarly thawed and lysed by incubation in lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM 2-mercaptoethanol, 0.25% Triton-100X, 2 mg/mL 
lysozyme, with protease inhibitors) followed by sonication. After centrifugation, lysates were applied to 
glutathione agarose (Sigma), the column was washed, and proteins were eluted in 6.8 mg/mL reduced 
glutathione. Peak fractions for each substrate were pooled and dialyzed into 50 mM HEPES pH 7, 50 mM 
NaCl. 
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After isolation, the purity of all proteins was verified by SDS-PAGE followed by Coomassie Brilliant Blue 
staining.  Protein concentration was determined by either Bradford (Bio-Rad) or BCA (Thermo Scientific) 
protein concentration assays. Purified proteins were flash frozen in liquid nitrogen and stored at -80°C. 
 
Fluorescence polarization assay: Fluorescence polarization (FP) studies were carried out as previously 
described [126]. Briefly, the FP tracer was composed of a peptide derived from Hsp72/HSPA1A 
(GSGPTIEEVD) that was coupled at the N-terminus to 5-carboxyfluorescein (5-FAM) via an aminohexanoic 
acid spacer. This tracer (KD ~ 0.51 ± 0.03 µM) was used in a competition FP format to estimate binding to 
CHIP. Tracer concentration was 1 µM, and the CHIP concentration was 0.5 µM in a total volume of 20 µL 
in 50 mM HEPES, 10 mM NaCl, 0.01% Triton X-100, pH 7.4. The final DMSO concentration was 
approximately 1%. After mixing the components, each black 384 well plate (Corning) was covered from 
light and incubated at room temperature for 30 min. Polarization values were measured at Excitation 
485 nm and Emission 530 nm using a Molecular Devices Spectramax M5 plate reader (Sunnyvale, CA). 
Data were analyzed using GraphPad Prism 6 software. 
 
CHIP in vitro ubiquitination assay: Reactions were initiated by pre-incubating 125 nM Ube1, 1 µM UbcH5b, 
and 200 µM ubiquitin for 30 min at 37°C in 50 mM HEPES pH 7.0, 50 mM NaCl, 2 mM ATP, and 4 mM 
MgCl2. In a separate reaction tube, 10 µM purified CHIP and up to 500 µM compound dissolved in DMSO 
were combined and incubated for 15 min on ice, followed by the addition of 3 µM of either GST-Hsc70395-
646 or GST-AT-3 JD, which served as substrates for CHIP-dependent ubiquitination. DMSO in these 
reactions was <5%. After pre-incubation, the ubiquitin-charged E1/E2 mixture was dispensed after which 
all reactions proceeded for 15 min at 37°C. Reactions were quenched by addition of SDS sample buffer 
supplemented with 50 mM EDTA, 20 mM DTT. Quenched reactions were resolved by 10% SDS-PAGE, 
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transferred to nitrocellulose membranes and western blotted with either anti-GST HRP-conjugated 
antibody to visualize substrate ubiquitination, or anti-ubiquitin primary antibody, followed by an HRP-
conjugated secondary antibody to visualize the amount of total ubiquitination. Products were visualized 
using a Bio-Rad ChemiDoc XRS+ imaging system and quantified using ImageJ software. 
 
3.4.13 Experimental assays involving PDK1 
 
Materials: Soluble biotin-phosphatidylinositol3,4,5-triphosphate, biotin-PIP3, labeled with biotin at sn1-
position, was from Echelon Biosciences Inc. Bio-GST, used as a control in the alphascreen system, 
corresponds to biotinylated GST, (Perkin-Elmer). The peptide substrate T308tide (KTFCGTPEYLAPEVRR; > 
75% purity) were synthesized using Pepscan. 
 
PDK1 constructs: PDK1 CD (1-359) and PDK1 PH (360-556) were cloned in pEBG2T vector in frame with 
GST, expressed in HEK293 by transient transfection and purified using glutathione-sepharose, as 
described previously for different GST-fusion constructs [127].  
 
Alphascreen interaction assay: The interaction between GST-PDK1 PH (10 nM) and biotin-PIP3 (20 nM) 
was measured using alphascreen technology (Perkin-Elmer), a bead-based proximity assay. The 
displacement of the interaction by Wortmannin was performed as previously described for the catalytic 
domain of PDK1 [128, 129]. Briefly, the assays were performed in a final volume of 25 µL in white 384-
well microtiter plates (Greiner Bio-One), including the interacting partners in a buffer containing 50 mM 
Tris-HCl pH 7.4, 100 mM NaCl, 2 mM DTT, 0.01% (v/v) Tween-20, 0.1% (w/v) BSA, and the corresponding 
concentration of the compound (1% final DMSO concentration). 5 µL of beads (anti-GST conjugated 
acceptor beads and streptavidin-coated donor beads) at a 20 µg/ml (microg/ml) were then added to the 
mixture and after an incubation of 60 minutes, alphascreen counts were measured in an EnVision 
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Multiplate reader. To set-up the assays, cross-titration experiments were performed, where the 
concentration of both interacting partners were varied. The concentration of binding partners in the 
assays were chosen so that both inhibitors and enhancers of the interaction could be identified. Controls 
using Bio-GST were performed to rule out unspecific effects on the biotin-GST alphascreen interaction 
assay system. 
 
PDK1 protein kinase activity assay: The in vitro activity of PDK1 was tested using 100-300 ng purified 
protein, following the transfer of 32P from radiolabelled [g32P]ATP to the polypeptide substrate T308tide 
at room temperature (22 °C) in a mix containing 50 mM Tris pH 7.5, 0.05  mg/ml BSA, 0.1%  -
mercaptoethanol, 10 mM MgCl2, 100 µM [g32P]ATP (5-50 cpm/pmol) and 0.003% Brij, as previously 
performed. [129]  
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3.5 SUPPLEMENTARY FIGURES  
 
 
 
Figure 3.8. Comparing random forest approaches with a random classifier for predicting known targets 
of validation compounds. The red arrow indicates the success rate of on-the-fly random forest and the 
green arrow represents the two-level random forest. 
 
 
 
Figure 3.9. ZINC compounds weakly disrupt CHIP binding to chaperone peptide as measured by 
fluorescence polarization. Results are the average and standard error of the mean of two experiments 
each performed in triplicate. 
  
 93 
 
Figure 3.10. CHIP inhibitors prevent ubiquitination by CHIP in vitro. (a) Anti-GST western blot showing 
substrate ubiquitination by CHIP in reactions treated with high ranked (2.1, 2.2) and low ranked (2.5) 
compounds. (b) Anti-ubiquitin western blot showing total ubiquitination by CHIP in reactions treated with 
high ranked (2.1, 2.2) and low ranked (2.5) compounds. 
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Figure 3.11. Predicted CHIP inhibitors prevent ubiquitination of an alternate substrate. (A) Anti-GST 
western blot showing AT-3 JD substrate ubiquitination by CHIP in reactions treated with compounds. (B) 
Quantification of all reactions as in A treated with up to 500 µM compound 2.1, 2.2, or 2.6, normalized to 
ubiquitination by a DMSO treated control (all compounds: N=4). 
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Figure 3.12. Comparison of gene expression-based and pharmacophore-based virtual screens against 
CHIP. HSP90 shows structure of the CHIP (grey) - HSP90 (magenta) interface (PDB ID: 2C2L [103]), 
indicating the hydrophobic (green spheres) and polar contact (blue surface / dashed lines) 
pharmacophores used to screen the ZINC database. Strong binders show predicted binding modes for 
compounds 2.1 and 2.2 from the LINCS screen, which showed the strongest FP signal and robust inhibition 
of CHIP ligases activity. Interestingly, 2.1 and 2.2 are the only predicted hits to make a novel hydrogen 
bond to CHIP residue Q102, a contact whose importance is not obvious from the cocrystal structure. Weak 
binders show predicted binding modes for compounds 2.3 and 2.4 from the LINCS screen, and compounds 
1.1, 1.2, and 1.7 from the ZINC screen, which showed modest FP signal. Non-binders show predicted 
binding modes for non-binding LINCS compounds 2.5 and 2.6, and non-binding ZINC compounds 1.3 – 1.6. 
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3.6 SUPPLEMENTARY TABLES 
 
 
Table 3.4. The cellular localization of successful and unsuccessful drug targets enriched by gene 
ontology. P-values were computed by intersecting proteins assigned to GO terms listed below with 
proteins in the sets compared (successful and failed) using the hypergeometric distribution. 
 
  Cellular Component p-value 
Successful 
Targets 
proteasome core complex 7.81E-37 
proteasome core 1.10E-28 
proteasome alpha-subunit 5.68E-18 
cytosol 7.53E-12 
protein complex 1.88E-11 
Failed 
Targets 
transmembrane transporter complex 7.77E-15 
sodium-exchanging ATPase complex 4.42E-14 
cation-transporting ATPase complex 8.74E-13 
plasma membrane part  2.19E-11 
chloride channel complex 2.33E-09 
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Table 3.5. Predicted HRAS/KRAS-targeting compounds purchased for experimental validation. ‘Target 
Rank’ indicates the ranking of HRAS/KRAS in the RF-predicted list of potential targets for each compound. 
‘Cpd Rank’ indicates the structure-based ranking of the compound after docking all candidate inhibitors.  
 
Target Name ID Target Rank Cpd Rank 
HRAS 
BRD-A18725729 BRD-A18725729 90 52 
BRD-K00954209 BRD-K00954209 73 1 
BRD-K95858622 BRD-K95858622 92 34 
mefloquine BRD-K40645748 56 34 
procaterol BRD-A22684332 99 70 
RS-39604 BRD-K20742498 21 81 
KRAS 
KM_00799 BRD_K87375115 6 84 
phloretin BRD_K15563106 65 3 
zardaverine BRD_K37561857 34 67 
BRD_K85275009 BRD_K85275009 1 80 
amodiaquine BRD_K91290917 35 32 
 
 
Table 3.6. Predicted CHIP-targeting compounds purchased for experimental testing. ‘Chip Rank’ 
indicates the ranking of CHIP in the random-forest predicted list of potential targets for each compound. 
‘Cpd Rank’ indicates the structure-based ranking of the compound after docking all candidate inhibitors. 
 
Cpd # Name ID CHIP Rank Cpd Rank 
2.1 phenolphthalein BRD_K19227686 2 22 
2.2 HSP90_inhibitor BRD_K65503129 2 4 
2.3 axitinib BRD_K29905972 8 13 
2.4 BRD_K59556282 BRD_K59556282 11 92 
2.5 SB_431542 BRD_K67298865 34 17 
2.6 MW_STK33_2B BRD_K78930611 51 16 
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Table 3.7. Symbols and notations. 
 
Symbol Meaning 
d Index for a drug 
c Index for a cell line 
g Index for a gene 
ND Total number of genes 
NC Total number of cell lines 
Cd The set of cell line indeces for drug d 
Pd The set of protein target indeces for drug d 
Gc The set of knockdown gene indeces for cell line c 
Td The intersection of knockdown gene indeces Gc for all cell lines in Cd 
Ndc Number of experiments for applying drug d to cell line c 
Ngc Number of experiments for knocking down gene g in cell line c 
Ng Neighbors, or protein-protein interaction partners, of gene g 
Δ Drug-response data 
Γ Gene-knockdown data 
Ψ Control data 
Ω Full feature data 
Xd Training data derived from drug d 
yd Training label derived from drug d 
νd Negative (non-target) genes for drug d 
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Table 3.8. Summary of constructed feature sets. Note that different feature sets can have different 
dimensions (some contain values for each of the cell lines, etc…). The exact dimension and content of 
each feature set is discussed in the text. 
 
Feature Name Symbol Meaning 
Direct 
Correlation fcor 
Correlation between a drug treatment experiment and a 
gene knockdown experiment 
Indirect 
Correlation fPC 
Fraction of the known binding partners of a gene in the top 
X correlated knockdown experiments 
Cell Selection fCS 
Correlation between a drug treatment experiment and the 
control experiment for the cell line 
PPI Expression fPE 
The average or the max (absolute value) expression for the 
known binding partners of a gene 
 
 
 
Table 3.9. Cell lines included in the validation dataset. The number of drugs, knockdown genes, and 
control experiment are shown. For a given cell line, we only include drugs that have their target 
knockdown experiments available in that cell line. 
 
Cell Line Drugs Knockdowns Controls 
A549 188 11947 52 
MCF7 180 12031 54 
VCAP 175 13225 56 
HA1E 172 11968 53 
A375 143 11696 58 
HCC515 129 7828 52 
HT19 96 10185 52 
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3.7 ADDITIONAL FILES 
Additional File 3.1. (additional_file_3.1.xls) Results of testing our random forest classifier on the 123 
FDA approved drugs profiled in 4-6 LINCS cell lines after having trained our model on the 29 FDA 
approved drugs profiled in all 7 LINCS cell lines. The rank of the highest-ranking known target for each 
compound is listed next to their LINCS ID. We achieve top-100 predictions for 32 drugs, a 26% success 
rate.  
Additional File 3.2. (additional_file_3.2.xls) The names and LINCS IDs of the validation compounds 
shown in Figure 3.2. 
Additional File 3.3. (additional_file_3.3.xls) Structural enrichment of random forest predictions for 
validation hits and comparison with existing methods. Table lists the 63 `hits' from our validation drug 
set, including their names, LINCS ID and the number of top-100 predicted targets that had structures 
available in the PDB. The ranking of the known targets for each compound are shown after our genomic 
random forest target prediction (GEN), and after our structural re-ranking (STR), along with the 
percentile rankings produced by alternative target prediction methods HTDocking (HTD) and 
PharmMapper (PHM). STR, HTD, and PHM values of 100 indicate that the structure of the known target 
either is not known or was not included in the set of potential targets used by the method. 
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4.0 DRUGGING THE TNF-INDUCED NF-kB SIGNALING NETWORK 
 
 
 
 
4.1 INTRODUCTION 
 
The nuclear Factor kB (NF-kB) transcription factor regulates expression for hundreds of genes that 
mediate signals for inflammation, proliferation, and survival [130-135]. Deregulation of NF-kB has been 
linked to chronic inflammation in addition to development and progression of various cancers [136-139]. 
As a pleiotropic regulator of disease-related genes, chemicals that modulate the NF-kB signaling pathway 
have therapeutic relevance. However, the complexity of this pathway makes it difficult to understand the 
mode of action and side effects of these agents. Traditional ‘target-centric’ drug development strategies 
that prioritize single-target potency in-vitro, and the difficulty of modulating specific protein-protein 
interactions in-vivo, exacerbates the challenges of drugging this pathway in the cell [140]. Not surprisingly, 
there are no clinically approved inhibitors of NF-kB pathway components. 
 
An alternative approach is a network-centric strategy to identify small-molecules that inhibit a signaling 
pathway. Tumor necrosis factor (TNF) is an inflammatory cytokine that initiates dynamic intracellular 
signals when bound to its cognate TNF receptor (TNFR1). In response to TNF, the IkB-kinase (IKK) complex 
is rapidly recruited from the cytoplasm to poly-ubiquitin scaffolds near the ligated receptor where it is 
activated through induced proximity with its regulatory kinase, TAK1 (Figure 4.1a) [141-146]. When 
phosphorylated by activated IKKs, NF-kB inhibitor proteins (IkB) are degraded and NF-kB accumulates in 
the nucleus to regulate transcription. Because the components of the molecular network are well-defined, 
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disruptors of the signaling network can be predicted from transcriptomic alterations that are shared by i) 
exposure to small molecules, and ii) genetic knockdowns of pathway components. Through structural 
screening and live-cell experiments that monitor signaling dynamics in single cells, the dominant mode of 
action on the signaling network can be inferred.  
 
To meet this challenge and demonstrate a network-centric strategy for targeting TNF-induced NF-kB 
signaling, we focused on differential gene expression signatures from the NIH Library of Integrated 
Network-Based Cellular Signatures (LINCS) L1000 dataset [147]. We compared transcriptional profiles 
between genetic knockdowns of proteins in the NF-kB signaling pathway and responses of the same cell 
types to thousands of distinct bioactive compounds. Using a random forest classification model, we 
identified compounds whose transcriptomic perturbations resembled genetic disruption. For each 
compound, the probability of a compound-protein interaction was evaluated in terms of ‘direct’ 
correlation with the knockdown signatures, and ‘indirect’ correlations with knockdown signatures of other 
proteins in the network. Correlations that cluster on specific protein subnetworks (Figure 4.1a) suggest 
chemical inhibition within the signaling pathway that mimic genetic inhibition of those network 
components (Figure 4.4). Note that because of the connectivity of the protein interaction network, it is 
difficult to precisely identify a single binding target from the gene profiles alone. For example, a compound 
that disrupts TRADD or TRAF2 might have similar signatures relative to the knockdown of upstream and 
downstream genes in the pathway such as TNFR1, UBC, or NEMO. Hence, the genomic screening would 
be expected to show all of these as targets with some probability. 
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Figure 4.1. Small molecule treatments produce transcriptional responses in that correlate with genetic 
knockdowns of proteins involved in NF-kB signaling. (a) Schematic of the cytoplasmic multi-protein 
complex that assembles following ligation of TNF to TNFR1. The color for each protein species in the 
complex is the average Pearson correlation between gene expression profiles for the species’ genetic 
knockdown and the transcriptional response to compounds 2 and 3. (b) Correlation between 
transcriptomic perturbations by compounds 1, 2, and 3 and the knockdown of genes functionally involved 
in NF-kB according to the KEGG PATHWAY Database. (c) Unbiased molecular docking predicts binding of 
compounds 2 (yellow) and 3 (magenta) to the TRADD-binding interface of TRAF2. Hydrogen bonds with 
key TRAF2 interface residues are indicated by dotted lines. 
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4.2 RESULTS 
 
To identify compounds that inhibit TNF-induced NF-kB signaling we focused on disruptions of the TNFR1 
complex at the level of TRADD, TRAF2, and RIP1, interacting proteins that are necessary to form ubiquitin 
scaffolding upon TNF stimulation (Figure 4.1a). We reasoned that these disruptions will restrict the 
dynamics of IKK recruitment and effectively prevent transcriptional signals encoded through nuclear 
translocation of NF-kB [148]. Transcriptional signatures for more than 860 compounds showed strong 
correlations with knockdown of TRADD, TRAF2, and RIP1, so we focused on three compounds (1: BRD-
K43131268; 2: BRD-K95352812; and 3: BRD-A09719808) that also correlate broadly with NF-kB signaling 
in the KEGG pathway database (Figure 4.1b). For compounds 1, 2, and 3 respectively, predicted targets 
from our dataset include: TRAF2, UBC, NFKB1, and RIP1; TRAF6, NEMO, TRAF2, NFKB1, UBC, TAB2, and 
IKKb; and, NFKB1, TRAF2, UBC, UBB and NEMO. Furthermore, compounds 2 and 3 both showed significant 
correlations with HOIL, TAK1, clAP1/2 and UbcH5 knockdowns (Figure 4.1a). Compounds 2 and 3 also had 
similar chemical structures (Figure 4.1c) and transcriptional profiles (Figure 4.1b), strongly suggesting a 
similar mechanism of action. 
 
To better predict the likely target of these compounds, we performed molecular docking on available 
structures/domains in the pathway. The only target suggested by our screening of available structures 
was TRAF2. The predicted binding modes of all three compounds corresponds to the same binding site as 
that of TNFR2 (PDB code 1CA9 [149]) and TRADD (PDB code 1F3V [150]) with TRAF2. Compounds 2 and 3 
formed hydrogen bond contacts with TRAF2 residues S453, S454, S455, and S467, which are predicted to 
compete with TRADD interface residues Q143, D145, and R146 based on the co-crystal (Figure 4.1c). 
Compound 3 is predicted to be a stronger binder due to the extra hydrogen bond formed by its amide 
group with TRAF2 residue G468. Competitive binding should disrupt the native TRADD-TRAF2 interface 
and could prevent maturation of the full TNFR1 signaling complex by promoting dissociation or allosteric 
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stabilization of a non-native conformation.  The predicted binding mode of compound 1 is less specific 
and did not form any of the aforementioned contacts (Figure 4.5). Thermal shift assays showed that 
compounds 2 and 3 respectively exert a subtle to moderate dose-dependent stabilizing effect on full 
length TRAF2 (Figure 4.2a, b), suggestive of direct binding, whereas compound 1 did not show a clear 
trend (Figure 4.6). We note that the observed thermal shifts are consistent with the relatively small 
stability effect that the compounds are expected to exert on the stable trimer formed by the soluble full 
length TRAF2 protein [149].   
 
 
 
Figure 4.2. Thermal shift assays indicate moderate dose-dependent stabilization of TRAF2 by 
compounds 2 and 3. Normalized melt curves (left) and melting temperature (Δtm; right) of full length 
TRAF2 were recorded in the presence of DMSO or indicated concentrations of (a) compound 2 and (b) 
compound 3. The rightward shift of the melt curve in the presence of compounds, quantified by the Δtm 
in replicate experiments, suggest increased thermal stability of the protein-compound complex. 
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We set out to determine whether the compounds are effective inhibitors of NF-kB signaling in living cells. 
For this, the endogenous gene locus for the transcriptionally active RelA subunit of NF-kB was modified 
using CRISPR/Cas9 to encode a fluorescent protein (FP) fusion in U2OS cells (Figure 4.7), a cell line that 
forms IKK-recruiting polyubiquitin scaffolds in response to TNF [151]. Responses of single cells exposed to 
TNF showed transient and variable translocation of NF-kB into the nucleus when measured from time-
lapse images (Figure 4.3a), comparable with other human cancer cell lines that express FP-RelA fusions 
[148, 152, 153]. When cells were pre-treated with compounds 2 and 3 before exposure to TNF, nuclear 
mobilization of NF-kB was reduced in proportion with the concentration of the inhibitory compound 
(Figure 4.3b). To quantify the compounds’ effect on NF-kB dynamics, each single-cell trajectory was 
decomposed into a series of descriptors (Figure 4.3c) that transmit information within the cell about 
extracellular TNF [152]. Although some descriptors did not show a clear trend (Figure 4.8), the most 
informative descriptor (area under the fold change curve, or ‘AUC’) was significantly reduced by 1µM 
pretreatment with either compound before exposure to TNF, and most descriptors were nearly 
indiscernible from untreated control cells when pretreated with 10µM (Figure 4.3d). By contrast, 
compound 1 did not significantly alter the TNF-induced dynamics of nuclear NF-kB (Figure 4.9). These data 
suggest that compounds 2 and 3 target the upstream TNFR1 multi-protein complex in the signaling 
network to restrict NF-kB activation.  
 
To test this hypothesis, and directly observe the recruitment of IKK to the TNFR1 complex, we used 
CRISPR/Cas9 to target the γ-subunit of the IKK complex (also known as NEMO) for FP fusion in U2OS cells 
(Figure 4.10). FP-IKK was diffuse within the cytoplasm and rapidly localized to punctate structures near 
the plasma membrane after exposure to TNF (Figure 4.3e). The number of punctate FP-IKK structures in 
single cells peaked at 15 minutes and dissolved within an hour of TNF stimulation (Figure 4.3f). Although 
the recruitment and dissolution dynamics of FP-IKK are prolonged when compared with a previous study 
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that overexpressed a fusion of mouse IKKγ [151], they are otherwise qualitatively similar. Consistent with 
our observations for NF-kB, the number of TNF-induced puncta were greatly reduced in single cells that 
were pretreated with compounds 2 or 3 before exposure to TNF (Figure 4.3f). Unexpectedly, the 
compounds also reduced the overall expression level of IKKγ (Figure 4.11) through an unknown 
mechanism that may relate to TRAF-dependent ubiquitination cascades that regulate the ambient 
stability of other NF-kB-inducing kinases [154]. 
 
 
  
 108 
 
Figure 4.3. Small molecules disruptors of NF-kB signaling reduce nuclear translocation of NF-kB and the 
formation of NEMO puncta in TNF-stimulated cells. (a) Time-lapse images of FP-RelA expressed from its 
endogenous gene locus in U2OS cells exposed to TNF. The nuclear subcellular compartment is indicated 
with a broken yellow line. Scale bar 20µm for all. (b) Single cell time courses of nuclear FP-RelA measure 
the change in the nuclear abundance of NF-kB in response to the indicated conditions. Red numbers 
indicate the number of single cell trajectories in each condition. (c) Descriptors used to quantify single cell 
responses. AUC, Max, and tmax, respectively, describe the area under the curve, the maximum, and the 
time of maximal nuclear FP-RelA fluorescence. Ratein and Rateout describe the maximal rate of nuclear 
entry and exit. (d) Box (first and third quartile) and whisker (1.5 times interquartile range) plots showing 
the condition-specific variation for descriptors of nuclear FP-RelA localization. Red bars indicate the 
median; * p<0.05, **p<<10-5, t test. (e) Time-lapse images of FP-IKK expressed from its endogenous gene 
locus in U2OS cells exposed to TNF. (f) Single-cell time courses for the number of FP-IKK puncta in cells 
stimulated with the indicated conditions. In all TNF conditions, a concentration of 10 ng/mL was used.   
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4.3 DISCUSSION 
 
 
Taken together our results show that compounds 2 and 3 inhibit the TNF-induced NF-kB signaling pathway 
by limiting the formation of the mature TNFR1 complex. We also highlight the much broader effects of 
disrupting a pathway component within the larger network, including the downregulation of IKKγ protein 
expression, and the limitations of single-target molecular modelling as a basis for drug design. The 
regulatory complexity of the NF-kB signaling pathway, which enables highly specific and stimulus-
dependent transcriptional responses, also confounds drug discovery efforts that do not account for 
network-scale responses to chemical disruption. Consequently, successful therapeutic intervention in 
complex signaling pathways may require a network-centric strategy guided explicitly by a compounds’ 
anticipated effects on signaling dynamics as a pharmacologic target. [155] 
 
Correlations in gene expression signatures and single-cell experiments can be used to respectively predict 
and validate the network effects of bioactive compounds, and structural analysis can further inform on 
their mechanism of action. Here, our models suggest that compounds 2 and 3 destabilize interactions 
between TRADD and TRAF-family proteins. Mechanistically, disruption at this upstream junction will 
preclude ubiquitin scaffold assembly, and this rationalizes the correlations observed between our 
compounds and knockdowns of UBB and UBC, in addition to other signaling proteins that are recruited to 
these poly-ubiquitin chains (see Figure 4.1a).  
 
Although the LINCS dataset does not explicitly report the transcriptional response of cells to TNF in the 
presence of chemical or genetic perturbations, compounds that impinge on TNF-induced dynamics could 
still be inferred using a machine learning algorithm with prior knowledge of the signaling network. This 
pipeline therefore represents an alternative strategy to single-target-based drug discovery that can be 
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more generally applied to discover novel inhibitors of protein subnetworks in a variety of signaling 
pathways. Because mechanism of action is not constrained a priori, it is possible to discover a chemical 
agent that disrupts multiple points in the same protein subnetwork, or to predict chemical combinations 
that produce specific network-level responses. It is unlikely that the “magic bullet” drug discovery 
paradigm will uncover the full therapeutic potential of compounds that modulate dynamic intracellular 
signals, such as the TNF-induced NF-kB signaling pathway. Rather, more effective drug development 
efforts may require approaches like the one presented here, that embrace the complexity of regulatory 
networks and dynamic phenotypes associated with their disruption. 
 
 
 
4.4 METHODS 
 
 
4.4.1 Analysis of gene expression data  
 
Preparation and analysis of gene expression (GE) data was performed as described in Chapter 3.4. Briefly, 
gene knockdown (KD) and compound treatment GE signatures were extracted from the LINCS L1000 
Phase I and Phase II datasets (GEO accession IDs: GSE70138 and GSE92742). We collected signatures for 
the 1680 small molecules and 3104 gene KD experiments that had been performed in at least four of the 
seven most common LINCS cells lines (A549, MCF7, VCAP, HA1E, A375, HCC515, HT19). We hypothesized 
that compounds that disrupt the TNF-inducible NF-kB signaling pathway should produce similar network-
level effects, and thus similar differential GE signatures, to genetic knockdowns of proteins in the pathway. 
Thus, for each compound – KD signature pair in our dataset, we computed several cell-specific 
quantitative features, most importantly: 
 
Direct correlation: the Pearson correlation coefficient between the compound treatment and the 
gene KD expression signatures in the given cell line, and 
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Indirect correlation: the fraction of the KD protein’s interaction partners, as defined by BioGrid[86], 
whose respective KD signatures were highly correlated with the compound signature. 
 
Three additional features, quantifying baseline drug activity in the cell and the maximum & average 
compound-induced differential expression levels of NF-kB pathway proteins[156], were also calculated 
and used in subsequent classification.  
 
Using a Random Forest (RF) classifier trained the expression signatures of 152 FDA-approved drugs with 
known mechanism(s) of action (see Chapter 3.4), features for every compound-KD pair (n=5,214,720) 
were used to predict the probability that the compound would inhibit the KD protein’s interaction 
network. The top-100 predicted interactions for each compound were extracted, and compounds whose 
predicted targets were enriched in TNF-induced NF-kB signaling genes (n=501) were collected for 
structural analysis. 
 
4.4.2 Structural analysis 
 
Structural docking of RF – predicted inhibitors proceeded as previously in Chapter 3.4. Briefly, 
representative crystal structures of TNF-inducible NF-kB signaling proteins (Supplementary Fig. 1) were 
mined from the PDB [157], optimizing for sequence coverage, structural resolution, and structural 
diversity. Domain structures were available for all proteins in Figure 4.1a with the exception of IKKa. 
Potential small-molecule binding sites on each protein structure were identified by clustering the output 
of computational solvent mapping software FTMap [119]. RF-predicted inhibitors were docked to 
predicted binding sites on each protein structure using smina [91], and a prospectively validated pipeline 
[90, 92]. Three promising candidate inhibitors of TRAF2, which showed both biophysical complementarity 
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and broad spectrum transcriptomic correlations with knockdowns in the pathway, were purchased from 
MolPort for experimental validation. 
 
4.4.3 Thermal shift assay and analysis 
 
TRAF2 - compound interactions were measured by fluorescence-based thermal shift using an Applied 
Biosystems ABI QuantStudio(TM) 6 Flex System. All assay experiments used 1uM GST-TRAF2 (Rockland) 
per well and 2 X Sybro Orange (Invitrogen) in a buffer containing 50mM HEPES, pH 7.5, 150Mm NaCl in a 
total reaction volume of 15ul in 384 well plates. Compounds were diluted with DMSO, and each reaction 
had a final DMSO concentration of 1.5%. PCR plates were covered with optical seal, shaken, and 
centrifuged after protein and compounds were added. The instrument was programmed in the Melt 
Curve mode and the Standard speed run. The reporter was selected as Rox and None for the quencher. 
Each melt curve was programmed as follows: 25 °C for 2 min, followed by a 0.05°C increase per second 
from 25 °C to 99 °C, and finally 99°C for 2min. Fluorescence intensity was collected continuously. In the 
Melt Curve Filter section, X4 (580 ±10)-M4 (623±14) was selected for the Excitation Filter-Emission Filter. 
The raw data was extracted in MS-Excel format. Each melt curve was normalized between 0 and 1 and the 
midpoint of the curve was used to determine the melting temperature. 
 
4.4.4 Establishing EGFP- RELA /IKKγ CRISPR Knock-in Cells 
 
Construction of Repair Templates for EGFP-IKKγ CRISPR Knock-in: The RelA repair template consisted of 
DNA sequences for a left homology arm (LHA -544bp, chromosome 11_65663376 - chromosome 
11_65662383) followed by an EGFP coding sequence with a start codon but no stop codon and a sequence 
encoding 3x GGSG linker followed by a right homology arm (RHA +557bp, chromosome 11_65662829 - 
chromosome 11_65662276) were assembled from plasmids synthesized by GeneArt. Synonymous 
mutations that are not recognized guide RNAs were introduced to prevent interaction the repair template 
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and Cas9. IKBKG DNA sequences for left homology arm (LHA -861bp, chromosome X 154551142- 
chromosome X 154552002) and right homology arm (RHA +797bp, chromosome X_154552006 - 
chromosome X 154552798) were amplified from Hela genomic DNA using the following primer pairs: 
IKBKG_LHA_F: 5’GGG CGA ATT GGG CCC GAC GTC GTT TCA CCG TGT TAG CCA GG3’, IKBKG_LHA_R: 5’ CAC 
ATC CTT ACC CAG CAG A3’; IKBKG_RHA_F: 5’AGA GTC TCC TCT GGG GAA GC3, IKBKG_RHA_R: 5’CCG CCA 
TGG CGG CCG GGA GCA TGC GAC GTC AGT CTA GGA AAG AAC TCC CCA GTC3’. In order to generate the 
fragment containing EGFP overlapping with LHA and RHA, we synthesized the sequence from GeneArt, 
then we amplified the sequence containing EGFP with the primer pairs: IKBKG_EGFP_F 5’ TCT GCT GGG 
TAA GGA TGT G3’, IKBKG_EGFP_R 5’ GCT CTT GAT TCT CCT CCA GGC AG 3’. After PCR products were 
purified, the fragments LHA, RHA, EGFP were cloned to pMK plasmid that was digested with AatII by 
gibson assembly from NEB. 
 
Construction of Guide RNA: The guide RNAs were designed by the CRISPR Design Tool 
(http://crispr.mit.edu). Oligonucleotide pairs Rel A sg1 (top): 5’-CACCGCTCGTCTGTAGTGCACGCCG-3’, Rel 
A sg1 (bottom): 5’-AAACCGGCGTGCACTACAGACGAGC-3’; RELA Sg2 (top)   5’-
CACCGAGAGGCGGAAATGCGCCGCC-3’, RELA Sg2 (bottom)   5’- AAACCGCGGCGCATTTCCGCCTCTC-3’; 
IKBKG Sg1 (top) 5’-CACCGGCAGCAGATCAGGACGTAC-3’, IKBKG Sg1 (bottom) 5’-
AAACGTACGTCCTGATCTGCTGCC-3’; and IKBKG Sg2 (top)   5’-CACCGCTGCACCATCTCACACAGT-3’, IKBKG 
Sg2 (bottom) 5’-AAACACTGTGTGAGATGGTGCAGC-3’ were cloned into the vector pSpCas9n (BB)-2A-Puro 
(PX462) (Addgene). The pSpCas9n (BB)-2A-Puro-IKKγ_gRNAs vector encoded the guide RNA and the Cas9 
nuclease with D10A nickase mutant. 
 
Transfection and Clone Isolation: U2OS cells (2 × 105 cells per well) were seeded in 6-well plates in 
complete growth medium. The following day, with pSpCas9n (BB)-2A-Puro-RELA/IKKγ_gRNAs and repair 
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template donor plasmids were linearized using BGLII, and cells were transfected using FuGENE HD 
(Promega) with a transfection reagent to DNA ratio of 3.5 to 1 and a total DNA amount of 4μg. After two 
weeks, cells were subjected to single cell sorting into 96-well plates using Beckman Coulter MoFlo Astrios 
High Speed. Cells underwent clonal isolation and a positive clone was identified via western blot and 
confirmed by live-cell imaging. 
 
4.4.5 Western blot analysis 
 
U2OS cells (parental and expressing EGFP-RelA/IKKγ via CRISPR Knock-in) were cultured for 24 hrs 
in complete growth medium. After treatments, cells were lysed in SDS-based lysis buffer consisting of 120 
mM Tris-Cl, pH 6.8, 4% SDS supplemented with protease and phosphatase inhibitors at 4°C for 30 
min. Protein extracts were clarified by centrifugation at 4°C at 12,000 × g for 10 min. Lysate protein levels 
were quantified by BCA assay (Pierce). Samples were separated by SDS-PAGE, 25 μg total protein per lane, 
then transferred to PVDF membranes. Blocking was done in 5% milk in TBS for 1 hour. Primary antibodies 
directed at RelA and β-actin (#4764 and #3700 respectively; Cell Signaling Technology), IKKγ and GAPDH 
(sc-8330 and sc25778 respectively; Santa Cruz) were diluted in 5% milk in TBS-T and incubated overnight 
at 4°C. Alexa 680/800-conjugated secondary antibodies (LICOR) were used in combination with an 
Odyssey (LI-COR) scanner for detection and quantification of band intensities. 
 
4.4.6 Live-cell imaging and analysis 
 
Live cells were imaged in an environmentally controlled chamber (37°C, 5% CO2) on a DeltaVision Elite 
microscope equipped with a pco.edge sCMOS camera and an Insight solid-state illumination module (GE). 
U2OS cells expressing FP-RelA/IKKγ were seeded at a density of 25000 cells/well 24 hours prior to live-cell 
imaging experiments on no. 1.5 glass bottom 96 well imaging plates (Matriplate). For imaging of FP-RelA 
nuclear translocation, live-cells were pre-treated with DMSO or indicated concentrations of compounds 
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for 2 hours before exposure to 100ng/ml TNF. Wide-field epifluorescence and DIC images were collected 
using a 20x LUCPLFLN objective (0.45NA; Olympus). Cells were imaged for at least 30 minutes prior to 
addition of compounds. For detection of IKKγ puncta, , live-cells were pre-treated with DMSO or indicated 
concentration of compounds for 2 hours before exposure to 100ng/ml TNF. Wide-field epifluorescence 
and DIC images were collected using a 60x LUCPLFLN objective. For all treatments, cytokine mixtures were 
prepared and pre-warmed so that addition of 120uL added to wells results in a final concentration as 
indicated. Time-lapse images were collected over at least 4 fields per condition with a temporal resolution 
of 5 minutes per frame. Quantification of nuclear FP-RelA localization and the formation IKKγ puncta from 
flat-field and background corrected images was performed using customized scripts in Matlab and ImageJ. 
 
4.4.7 Fixed-cell immunofluorescence and analysis 
 
For fixed-cell measurement of endogenous RelA (Supplementary Figure 4), U2OS cells were seeded into 
plastic bottom 96 well imaging plates (Fisher) at 6000 cell/well 24 hours prior to treatment. On the day of 
the experiment, media containing TNF was prepared at 15X the desired concentration for each well. 
Timing of TNF treatment was planned so fixation (0, 10, 30, 60, 90, 120 minutes) occurred simultaneously 
for all time points at the same time. Pre-warmed 15X cytokine mixture was spiked into wells and mixed. 
Between treatments the cells remained in environmentally controlled conditions (37°C and 5% CO2). 
 
At time zero, media was removed from the wells, 185 μL of PBS was used to wash the wells, and wells 
were incubated at room temp in 120 μL of 4% paraformaldehyde (PFA) in 1X PBS for 10 minutes. Wells 
were then washed 3X three minutes with 185 μL 1X PBS and then incubated in 120 μL 100% methanol for 
10 min at room temp. Next wells were washed 3X three minutes in PBS-T (1XPBS 0.1% Tween 20) followed 
by 120 μL of primary antibody solution (3% BSA PBS-T, 1 μg/mL NF-ĸB p65 F-6 (sc-8008; Santa Cruz)). 
Plates were wrapped in para-film and left to incubate at 4°C overnight. The following morning, wells were 
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washed 3X five minutes in 185 μL PBS-T followed by incubation for 1 hour in 120 μL of the secondary 
antibody solution (3% BSA PBS-T, 4 μg/mL Goat anti-Mouse IgG Alexa Fluor 647 (Thermo Fisher)). 185 μL 
PBS-T was used to wash the wells for 5 minutes and they were put into 120ul Hoechst solution (PBS-T, 
200ng/mL Hoechst) for 20 min. Finally, wells were washed five minutes with PBST and then 185 μL PBS 
was used to fill the wells and keep the cells hydrated during imaging. Cells were imaged using Delta Vision 
Elite imaging system at 20x magnification with a LUCPLFLN objective (0.45NA; Olympus). Analysis was 
done using Cell Profiler to segment cells and quantify median nuclear intensity values. Further analysis 
was performed using custom scripts in MATLAB. 
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4.5 SUPPLEMENTARY FIGURES  
 
 
 
Figure 4.4. Prediction pipeline used to identify small molecule inhibitors of TNF-inducible NF-kB 
signaling. Input includes cell-specific gene expression (GE) signatures from 1680 bioactive small molecules 
and 3104 gene knockdowns, taken from the LINCS L1000 dataset [147], and the protein interaction 
networks of knockdown genes, inferred from their BioGrid [86] – defined interaction partners. 
Correlations between compound and knockdown GE signatures and their distribution on the TNF-
inducible NF-kB pathway (see Figure 4.1a) are evaluated by a random forest classifier to predict candidate 
inhibitors. Structural models of pathway proteins are mined from the PDB [157] and used as molecular 
docking targets for candidates. Docking results are assessed to identify high-confidence predicted 
inhibitors.   
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Figure 4.5. Predicted binding mode of compound 1 to TRADD-binding interface of TRAF2. Hydrogen 
bonds are indicated with dotted lines. 
 
 
 
 
Figure 4.6. Thermal shift assays indicate no clear effect of compound 1 on TRAF2 stability. (a) Normalized 
melt curve of full length TRAF2 in the presence of DMSO or indicated concentrations of compound 1. (b) 
Melting temperature of TRAF2 in the presence of compound 1 are not significantly altered in replicate 
experiments. 
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Figure 4.7. Quantification of FP-RelA expression in U2OS cells. (a) Western blot of RelA in lysates from 
parental U2OS cells (P) and U2OS cells that were modified using CRISPR to express EGFP-RelA. The 
molecular weight of the dominant FP-RelA band in the CRISPR-modified cell line is shifted upward by 32 
kDa, consistent with the expected molecular weight of the EGFP fusion protein. The presence of the wild 
type RelA band in the CRISPR-modified cell line suggests that only one allele of the RelA-encoding gene 
integrated the EGFP-encoding sequence. (b) Subcellular localization of RelA from fixed-cell 
immunofluorescence images of parental U2OS cells (left) and FP-RelA quantified from CRISPR-modified 
live cells (right) exposed to 10 ng/mL TNF show similar temporal dynamics. 
 
 
 
 
Figure 4.8. Other descriptors of nuclear FP-RelA. Descriptors tmax (a) and Rateout (b) do not show 
statistically significant differences in response to TNF.        
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Figure 4.9. Compound 1 does not have a significant effect on FP-RelA translocation. (a) Single cell time 
courses measure the change in nuclear abundance of FP-RelA in cells exposed to 10ng/mL TNF after pre-
incubation with compound 1. (b) Descriptors of nuclear FP-RelA dynamics do not change significantly 
even in the presence of a high concentration of compound 1. 
 
 
 
 
Figure 4.10. Western blot of IKKγ. Western blot of IKKγ in lysates from parental U2OS cells (P) and U2OS 
cells that were modified using CRISPR to express EGFP-IKKγ. The molecular weight of the FP-IKKγ band in 
the CRISPR-modified cell line is shifted upward by 32 kDa, consistent with the expected molecular weight 
of the EGFP fusion protein. The absence of wild type IKKγ in the CRISPR-modified cell line suggests that 
both alleles of the IKKγ-encoding gene integrated the EGFP sequence. 
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Figure 4.11. IKKγ expression in the presence of compounds 2 and 3. (a) Western blot of IKKγ in lysates 
from CRISPR-modified U2OS cells in the indicated conditions. (b) Quantification of Actin-corrected IKK 
band intensity, normalized to control cells that were not pre-treated with compounds, suggest that the 
presence of compounds 2 and 3 significantly downregulate the expression of IKKγ. Indicated p values 
were calculated from t tests of biological triplicates. 
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5.0 DRUGQUERY: STRUCTURE-BASED SMALL MOLECULE VIRTUAL SCREENING OF HUMAN 
PROTEINS 
 
 
 
5.1 INTRODUCTION 
 
Rising efficacy- and safety-related failure rates in pharmaceutical development programs [3-5] suggest 
the decline of the target-centric “magic bullet” drug discovery paradigm and its emphasis on single-target 
in-vitro potency [158]. In its place are emerging more global, network-centric approaches that embrace 
the complex regulatory environments in which drugs function and seek to account for multi-target effects 
[159-161]. Considering that the average drug currently on the market exhibits activity towards six 
molecular targets [162, 163], often resulting in unexpected and unwanted side effects [164-167], this shift 
in focus away from single proteins and towards multi-target networks is perhaps a natural step. The new 
drug discovery paradigm of polypharmacology seeks to anticipate and exploit the off-target effects of 
promiscuous small molecules [159, 160, 168-170], raising an immediate need for robust methods of 
predicting the protein targets of bioactive compounds, or target fishing.  
 
As experimental approaches to target fishing are often cost- and time-inefficient [171], more efficient 
computational approaches that leverage existing data have become popular  [172, 173]. Many are ligand- 
or network-based methods that extrapolate from known interactions of compounds that are structurally 
or functionally similar to the query compound [65-69, 174-176]. The main alternatives are structure-based 
methods, which evaluate the 3-D complementarity of potential ligand-target pairs using their atomic 
structures [70-72, 111, 177]. With the rapid growth of protein crystal structures in the PDB [157], 
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structure-based methods like reverse molecular docking offer a number of advantages over ligand-based 
similarity searching such as being unbiased with respect to novel chemical scaffolds and being able to 
predict the query compound’s binding mode [72]. These features are highly desirable in a drug discovery 
context, where new chemistries are often being tested and where knowledge of binding mode is 
necessary for lead optimization [178]. 
 
Despite these advantages, there currently exist no user friendly, publicly available tools for reverse 
docking at a large scale (1000+ potential targets). Published reverse-docking software has either been 
decommissioned [70], is prohibitively slow [71], or is unavailable for public use [177, 179]. To fill this void, 
we present DrugQuery (DQ): a fast, user-friendly, and publicly available web server for reverse-docking-
based target fishing. The DQ target library currently contains 7957 predicted binding sites on 2069 high 
quality crystal structures of 1245 unique human proteins, all easily searchable and available for download. 
User-submitted small molecules, accepted in all standard molecular file formats, are docked against the 
DQ library using the smina implementation of AutoDock Vina [91, 180]. Results, including a ranked list of 
potential targets and the query compound’s predicted binding modes, are returned in hours for most 
small molecules, facilitating fast and easy target fishing for any chemist or biologist.   
 
On a validation set of 95 FDA-approved drugs with known protein targets, DQ achieved top-10 and top-
100 target prediction accuracies of 35% and 58% percent, respectively, with at least one known target 
ranked in to top decile for 68% of compounds. Within the same validation set, DQ correctly identified 
multiple known protein targets for 10 drugs with promiscuous activity. Remarkably, without re-docking, 
76% of successful predictions were associated with binding modes < 2 Angstrom RMSD from known bound 
configurations. On a separate validation set of 102 congeneric FXR-binding compounds taken from the 
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2017 D3R Grand Challenge 2, DQ achieved top-10 and top-100 target prediction accuracies of 27% and 
72%, respectively, with FXR ranked in to top decile for 86% of compounds. 
5.2 METHODS 
5.2.1 The DrugQuery target library 
The DQ target library currently contains 2069 high quality crystal structures of 1245 human genes. 
Representative structures were extracted from the Protein Data Bank (PDB) [157] using a previously 
described greedy algorithm8 that considers all available human protein structures of a gene and selects a 
small number that maximize total sequence coverage and structural resolution (see Chapter 3.4.8). The 
selection process accounts for conformational diversity by allowing multiple representative structures of 
a single domain if they are separated by backbone RMSD above a sliding threshold, which iteratively 
increases if too many representative structures are identified. The selection process does not explicitly 
consider the presence of cocrystalized ligands in protein structures, which reduces DQ’s bias towards 
known druggable targets. The distribution of representative structure counts for targets in the DQ library 
is shown in Figure 5.1a. 
8 https://github.com/npabon/generate_gene_models 
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Figure 5.1. Profiles of protein structures and predicted binding sites in the DrugQuery library. (a) 
Distribution of the representative structure counts for the 1245 genes in the DQ library. (b) Distribution 
of predicted binding site counts for DQ genes. (c) Distribution of predicted binding site counts for DQ 
protein target structures. 
Druggable binding sites on representative target structures are identified using the Atlas computational 
solvent mapping software employed by the FTMap web server [119], which has been demonstrated to 
identify known ligand-binding pockets with high accuracy [181]. Atlas output is clustered to combine 
fragments separated by a minimum distance of less than five Angstroms and (up to) the five largest 
clusters for each protein structure are stored in the DQ library, though occasionally fewer than five 
clusters are produced for a given target. The distributions of predicted binding site counts per-gene and 
per-target structure are shown in Figure 5.1b,c. 
5.2.2 Docking and scoring 
Docking to predicted binding sites is performed using the smina9 implementation of Autodock Vina [91, 
180]. Smina achieved state-of-the-art accuracy in both pose prediction and affinity ranking in recent 
community wide challenges including Drug Design Data Resource (D3R) and Community Structure-Activity 
Resource (CSAR) [90, 91, 182]. Docking to predicted binding sites is performed using a box padding of four 
9 https://sourceforge.net/projects/smina/ 
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Angstroms and standard rigid-receptor smina sampling and exhaustiveness parameters. For each 
compound – target – binding-site combination up to nine score-ranked docked poses are generated and 
saved to the DQ database. When dockings are completed for a given query compound, target structures 
are ranked by the top docking score achieved across each target's predicted binding sites.  
 
5.2.3 RMSD analysis of predicted binding modes 
 
During validation, when a crystal structure of a validation compound’s known binding pose was available 
in the PDB, we compared it to the binding mode predicted by DQ. We computed root-mean-squared 
deviations (RMSDs) between heavy atoms in the predicted vs. known poses using OpenBabel [183]. For 
compounds without reference binding poses available in the PDB, we searched for crystal structures of 
similar compounds bound to the same protein target. Structural similarity between compounds was 
evaluated in terms of the Tanimoto coefficient, computed using OpenBabel. “Similar” compounds were 
defined as having Tanimoto similarity > 0.7 to the validation compound. When a similar compound was 
available, the Python RDKit10 module was used to identify the maximum common scaffold (MCS) between 
it and the validation compound. We then used MCS heavy atoms to compute a partial RMSD between the 
DQ-predicted poses of the validation compound and the known binding mode of the similar compound. 
 
5.2.4 Web server  
 
The DQ interface was written using the Python web framework Django (2.0.4). DQ compounds, targets, 
and docking results are stored in a MySQL database (14.14). All cheminformatic operations, including 
validating user uploads and computing compound similarities, are carried out using the Open Babel (2.3.1) 
Python wrapper PyBel [183]. 3Dmol [184] is used to create interactive, three dimensional renderings of 
user-uploaded compounds and the targets in the DQ library. Job runtimes scale roughly with the number 
                                                        
10 http://www.rdkit.org/ 
 127 
of rotatable bonds in the compound and can range from one hour for small, rigid ligands to several hours 
for large, flexible molecules. 
 
 
5.3 USING DRUGQUERY 
 
 
5.3.1 Uploading a new small molecule 
 
On the DQ upload page (Figure 5.2a) users submit a ligand file and enter an email address to which a job 
completion notification will be sent. DQ accepts all standard small molecule file formats recognized by 
Open Babel [183] (SMI, SDF, PDB, MOL2, CIF, etc…). Before docking, DQ screens uploaded compounds 
against a database of previously uploaded compounds to check for duplicates. If the compound already 
exists in the DQ database, docking is skipped and the user is redirected to its existing results page. If not, 
DQ adds the compound to the database, assigns it a unique numerical ID reflecting the chronology of its 
upload, submits a docking job to the queue, and initializes an empty results page. The user is then 
redirected to the newly created results page (Figure 5.2b), which is populated upon completion of the 
docking job. 
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Figure 5.2. The DrugQuery user interface. (a) The DQ compound upload page. (b) The unpopulated results 
page for a newly-submitted compound.    
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5.3.2 Tracking a job 
Tracking the status of a docking job is achieved using by visiting the associated compound’s results page, 
accessible at drugquery.csb.pitt.edu/compounds/<id>/, which displays the status of the docking job 
(Figure 5.2b). To check a queued job’s place in line, users can inspect the DQ queue, accessible at 
drugquery.csb.pitt.edu/queue/. Once a docking job is completed, a link to the query compound’s results 
page is sent to the email address associated with the compound upload. 
5.3.3 Downloading results 
As shown in Figure 5.2b, a compound’s results page displays an interactive 3Dmol[184] rendering of the 
ligand and a table listing of the top-100 predicted protein targets. Each table entry lists the HUGO gene 
symbol of the target, the PDB and chain IDs of the protein model, the pocket ID of the predicted binding 
site, and the smina-predicted affinity score. There are several download options available to the user for 
retrieving results: (1) a columnated text file containing the complete target rankings and affinity scores, 
(2) a zipped directory containing the compound docking models (SDF format) and target structures (PDB
format) for the top-100 predicted targets, or (3) a zipped directory containing the complete set of 
compound docking models and structures for all DQ targets. Docking results (2) and (3) are organized 
hierarchically in directories by gene name, PDB ID, and chain ID. 
5.4 VALIDATION 
5.4.1  Predicting targets of FDA-approved drugs 
To demonstrate the usage of DQ we constructed a validation set of 95 FDA approved drugs with known 
targets listed in DrugBank [185] and ChEMBL [186] whose target genes were present in the DQ library 
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(Additional File 5.1).  Hereby referred to as Validation Set 1 (VS1), the distributions of known target counts, 
masses, and rotatable bonds for these compounds are shown in Figure 5.3. As several compounds had 
multiple known targets (Figure 5.3A), VS1 contained total of 169 pairwise interactions. 
 
 
Figure 5.3. Properties of FDA-approved compounds in Validation Set 1 (n=95). (a) Distribution of the 
number of known target genes present in the DQ library. (b) Molecular weight distribution. (c) Distribution 
of number of rotatable bonds. 
 
For each VS1 compound, DQ ranked the 2069 potential target structures by maximum docking score 
across the targets’ predicted binding sites. For 33 (35%), 55 (58%), and 65 (68%) of VS1 compounds, 
respectively, DQ predicted at least one known target in the top-10, top-100, and top-10% of potential 
targets. For 36 (21%), 66 (39%), and 84 (50%) of VS1 interactions, respectively, DQ predicted the known 
target in the top-10, top-100, and top-10%. Out of 30 compounds in VS1 with multiple known targets in 
the DQ library, DQ correctly ranked multiple targets in the top-10% for 10 (33%). The compound- and 
interaction-specific receiver operating characteristic (ROC) curves produced by DQ on VS1 are shown in 
Figure 5.4 and have area-under-the-curves (AUCs) of 0.89 and 0.80, respectively, demonstrating 
accuracies comparable to recent ligand-based [187] and genomic [80, 81] target prediction methods of a 
similar scale. 
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Figure 5.4. DrugQuery target prediction accuracy on Validation Set 1. (a) Compound-specific ROC curve, 
generated by sorting the 95 VS1 compounds by the rank of each one’s top-ranked known target. (b) 
Interaction-specific ROC curve, generated by sorting the 169 VS1 interactions by the rank of the known 
target for the relevant compound. 
One important advantage of DQ over alternative target prediction methods, however, is its ability to 
predict the 3D binding modes of the query compound to potential targets. 54 of the 84 VS1 interactions 
for which DQ predicted the known target in the top-10% had corresponding cocrystals in the PDB 
depicting the known binding mode of the interaction compound or a similar compound sharing a common 
scaffold (see Chapter 5.2.3 – RMSD analysis of predicted binding modes). Remarkably, for 34 (63%) of 
these interactions, the first DQ-predicted pose had RMSD < 2 Angstroms from the native pose, whereas if 
we considered the top-5 predicted poses then 41 (76%) had RMSD < 2 Angstroms (Figure 5.5). It is worth 
noting that re-docking – docking a compound into the receptor structure from a cocrystal in which it is 
already bound to the compound being docked – was explicitly avoided during validation by removing the 
offending target structures in the DQ library from consideration. 
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Figure 5.5. DrugQuery predicts native-like poses for compounds in Validation Set 1. (a) The DQ-predicted 
binding pose of calcifediol (magenta) aligned to a crystal structure (PDB ID: 1IE8) of KH1 (cyan) bound to 
the VDR protein (green). (b) The DQ-predicted binding pose of rimexolone (magenta) aligned to a crystal 
structure (PDB ID: 3MNE) of DEX (cyan) bound to the NR3C1 protein (green). (c) The DQ-predicted binding 
pose of olmesartan (magenta) aligned to a crystal structure (PDB ID: 4ZUD) of OLM (cyan) bound to the 
AGTR1 protein (green). 
 
5.4.2 Predicting targets of non-drug bioactive compounds 
 
To evaluate the performance of DQ in predicting the targets of non-drug small molecules, we constructed 
a second validation set (VS2) of 102 congeneric compounds from the 2017 community-wide D3R Grand 
Challenge 2. All VS2 compounds had known activity against the human protein NR1H4 (FXR), for which 
there are two representative structures (PDB IDs 4OIV & 3OKI) in the DQ library. The mass and rotatable 
bond distributions of VS2 compounds are shown in Figure 5.6a,b. For 28 (27%), 73 (72%), and 88 (86%) of 
VS2 compounds, respectively, DQ predicted FXR in the top-10, top-100, and top 10% of 2069 ranked 
potential targets. DQ’s VS2 ROC curve is shown in Figure 5.6c and has an AUC of 0.94. 
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Figure 5.6. Properties of compounds in Validation Set 2 (n=102) and DrugQuery target prediction 
accuracy. (a) Molecular weight distribution. (b) Distribution of number of rotatable bonds. (c) Compound-
specific ROC curve, generated by sorting the 102 VS2 compounds by FXR’s position among their ranked 
potential targets. 
 
As part of the D3R challenge, bound poses for 36 VS2 compounds were released to the PDB and we used 
them to evaluate the compounds’ DQ-predicted poses. For 10 (28%) of these compounds, the first DQ-
predicted pose had RMSD < 2 Angstroms from the native pose, whereas if we considered the top-5 
predicted poses then 16 (44%) had RMSD < 2 Angstroms (Figure 5.7). We observed that DQ’s 
comparatively weaker pose prediction accuracy for VS2 vs. VS1 was due largely to the fact that several 
VS2 FXR structures deviated significantly from the representative FXR structures in the DQ library (Figure 
5.8a). Predicted poses for these VS2 compounds were thus often “flipped” with respect to their true 
binding modes - maintaining specific, native-like hydrogen bond contacts but “swapping” the positions of 
nonspecific hydrophobic groups (Figure 5.8b,c). 
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Figure 5.7. Native-like predicted poses for compounds in Validation Set 2. DQ-predicted poses (magenta) 
aligned to bound cocrystal structures (green & cyan) for (a) FXR19, (b) FXR20, and (c) FXR22. 
 
 
Figure 5.8. Unique receptor conformations in Validation Set 2 produce “swapped” hydrophobic contacts 
in predicted poses. (a) Bound crystal structure of FXR4 (green & cyan) aligned to DQ’s representative FXR 
structure (orange, PDB ID 3OKI), highlighting significant conformational differences in binding-pocket-
adjacent protein regions. (b) DQ-predicted pose (magenta) of FXR14 aligned to bound cocrystal structure 
(green & cyan). Dashed black lines denote conserved, native-like hydrogen bonds. Solid black arrow 
indicates the “swapped” nonspecific hydrophobic groups of FXR14. (c) DQ-predicted pose (magenta) of 
FXR25 aligned to bound cocrystal structure (green & cyan). Native contacts and hydrophobic “swapping” 
indicated as in (b). 
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5.5 SUMMARY 
Predicting the protein targets of bioactive compounds has many critical applications in drug discovery 
including side effect prediction, drug repurposing, and the design of multi-target drugs. In lieu of costly 
wet lab target identification pipelines, ligand- and structure-based computational approaches have 
emerged. Of these, docking-based multi-target screening has the significant advantage of predicting the 
structural binding modes of query compounds. With the growth of available 3D protein structures in the 
PDB, docking-based methods are becoming increasingly well suited for target prediction and have in 
several cases predicted novel interactions that were subsequently verified experimentally [179, 188]. 
Currently, however, there are no fast and easy-to-use tools available to the scientific community for multi-
target docking at a large scale. 
Presented here is a public web server called DrugQuery (DQ) that meets this need – providing a simple 
and intuitive interface for to predict potential protein targets for small molecules of interest. The DQ 
library currently contains 2069 domain structures of potential protein targets from 1245 unique human 
genes and has the potential to scale up to the 10,000+ unique human proteins in the PDB. Using DQ, users 
can upload a compound of interest in any standard molecular file format and in a short time, a few hours 
for most small molecules, can easily download the complete DQ potential target rankings and the 
predicted binding modes of the query compound.  
DQ has been extensively tested for both target identification and binding site prediction on a chemically 
diverse validation set of 95 multi-target FDA-approved drugs, as well as a second validation set of 102 
congeneric FXR-binding compounds from the 2017 D3R Grand Challenge 2. In both cases, target ranking 
ROCs achieve AUCs above 0.89 (Figure 5.4, Figure 5.6c), demonstrating significant discriminative power in 
league with recent, non-structure-based, computational target prediction methods [80, 81, 187]. 
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Furthermore, DQ demonstrated multi-target prediction accuracy by correctly identifying multiple known 
protein targets for 10/30 multi-target drugs in VS1. In binding pose prediction, DQ achieved impressive 
accuracy considering that redocking was explicitly avoided. In VS1, DQ predicted poses with < 2 Angstrom 
RMSD from the native pose for 76% of compounds with bound cocrystal structures. In VS2, sub-2 
Angstrom RMSDs were achieved for 44% of compounds.  
DQ is in active development and there are a number of avenues for future improvement. In addition to 
expanding the DQ target library, we plan to implement compound-specific score normalization strategies 
to account for the so called “reverse docking scoring bias” - a phenomena that has been characterized for 
most available docking software [189] in which target predictions are artificially biased towards structures 
with larger, more hydrophobic cavities. Potential improvements to the representative structure selection 
process are also being considered, such as explicitly considering the presence of bound ligands and 
attempting to maximize binding-site diversity. 
5.6 ADDITIONAL FILES 
Additional File 5.1. (additional_file_5.1.xlsx) Table of compounds in Validation Set 1 and their known 
protein targets that have representative structures in the DurgQuery target library. 
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6.0 CONCLUSIONS AND FUTURE RESEARCH 
 
 
 
 
The research presented in this dissertation has focused on improving rational drug discovery by applying 
insights into the biophysics that regulate protein interactions and the network-scale effects of disrupting 
them. We focused on four major challenges in this arena: protein flexibility and selective promiscuity, 
protein target prediction for bioactive small molecules, disrupting complex signaling networks, and large-
scale structure-based target screening. Below, we will briefly recap our contributions to each of these 
areas and the computational approaches employed therein. 
 
In Chapter 2.0 we discussed our efforts to model how structural flexibility at the surface of immune 
checkpoint receptor PD-1 facilitates ‘selectively promiscuous’ binding – binding specifically to multiple 
protein ligands with structurally distinct binding interfaces. Using molecular dynamics simulations, we 
identified evolutionarily conserved “trigger” motifs on the ligands’ interfaces that, upon recognition by 
PD-1, displace polar Asn66 and transforms PD-1’s interface from flat and hydrophilic to flexible and 
hydrophobic. Ligand-specific, trigger-adjacent interactions then stabilize distinct bound-like receptor 
interfaces: a flat hydrophobic patch for PD-L1 and a large hydrophobic cavity for PD-L2. The importance 
of trigger interactions was demonstrated by a recent crystal structure of the blockbuster PD-1 – targeting 
antibody pembrolizumab, which, although having evolved via an entirely different pathway than PD-1’s 
cognate ligands, exploits analogous triggering interactions to displace Asn66. This, and the structural 
modelling of a recently patented PD-1 inhibiting macrocycle suggest the potential for triggering to guide 
rational drug design against challenging, high-impact targets like PD-1. Future work will in this area will 
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consist of: (1) incorporating conserved trigger motifs in virtual screening for inhibitors potentially capable 
of transforming hard-to-drug interfaces like PD-1’s into surfaces more amenable to small molecule 
binding, and (2) evaluating the generality of the trigger model of selective promiscuity by studying other 
flexible, multi-ligand regulatory proteins. 
 
In Chapter 3.0 we examined a hybrid genomic & structural pipeline for small molecule protein target 
prediction. Based on the hypothesis that small molecule protein inhibitors should yield similar 
transcriptomic responses in live cells to the genetic knockdown of the target protein, we trained a random 
forest classifier to predict drug-target interactions from gene expression data. We found that in addition 
to direct correlations between the gene expression signatures of drugs and the knockdowns of potential 
targets, accurate predictions required considering indirect correlations between the drug and other 
knockdowns in the potential target’s pathway. By refining our genomic predictions with structure-based 
modelling, we demonstrate that we can accurately predict the known targets of FDA-approved drugs as 
well as predicting previously unknown interactions, of which we validate several. Future work in this area 
will involve searching for ways to improve random forest classification accuracy, such as distinguishing 
between inhibitors and agonists during training or testing additional gene expression-based features. We 
may also explore the feasibility of employing alternative classification models like neural networks. 
 
In Chapter 4.0 we describe an extension of the genomic insight we gained from Chapter 3.0 and its 
application to identifying small molecule disruptors of the TNF-induced NF-kB signaling pathway. By 
virtually screening for compounds that produced broad-spectrum transcriptomic correlations with the 
genetic inhibition of proteins in the TNFR1 signaling complex, we identified two compounds that inhibited 
IKK recruited and prevented NF-kB in live cell fluorescence assays. Structural modelling suggested a 
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mechanism of action involving disruption of the native TRADD-TRAF2 interface, which would likely have 
downstream effects affecting ubiquitin scaffolding and recruitment of downstream signaling proteins.  
 
Finally, in Chapter 5.0 we present DrugQuery a first-of-its-kind public web server for docking-based small 
molecule target prediction. With over 2000 target structures and 1200 unique human genes currently 
represented in the DrugQuery library, we validated the server extensively in both target ranking and 
binding pose prediction contexts. DrugQuery’s simple web interface was designed with special 
consideration for potential users with limited computational cheminformatic or structural modelling 
experience, such that any biologist or chemist with a computer can quickly and easily obtain a ranked 
target list and predicted binding modes for their small molecule of interest. As a project in still in active 
development, we plan to scale-up the DrugQuery target library to exploit the full diversity of the Protein 
Data Bank as well as evaluate alternative strategies for rational representative structure selection. We 
may also make changes to DrugQuery’s backend docking and scoring pipeline as the Camacho group 
continues to participate in and learn from community-wide challenges in small molecule affinity ranking 
and pose prediction. 
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